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ABSTRACT 
 
 
Amyloid hypothesis is widely accepted as the centerpiece of Alzheimer’s disease 
(AD) pathogenesis. It is believed that the accumulation of amyloid beta (A) is 
the major deterministic factor of AD and the most important causative factor is 
the ratio of AAGamma()-secretase defines the length of A and is 
composed of at least four subunits: presenilins (PS1 or PS2), nicastrin (NCT), 
anterior pharynx-defective 1 (Aph-1), and presenilin enhancer 2 (Pen-2). They 
have been reported to have different roles in -secretase. For example, PS were 
believed as the catalytic components in -secretase; NCT was recognized as a 
substrate receptor; Pen-2 was regarded as necessary for the endoproteolysis of 
PS which necessary for the activity of PS; and Aph-1 was known as important for 
stabilization of the other -secretase components. However, these notions having 
been challenged by new and controversial findings, which make the functions of 
these components remain elusive. Therefore, the goal of my research projects is 
to address these controversial issues by systematically investigate the function of 
these components in -secretase activity and in apoptosis. 
    Our results demonstrate that 1) Aph-1 is dispensable for -secretase catalyzed 
processing of both Notch and amyloid beta precursor protein (APP); 2) NCT is 
crucial for APP processing, but is not absolutely required for Notch processing;  
3) Pen-2 is necessary for the processing of both Notch and APP processing;  
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4) Pen-2 is the most important component for recruiting substrates; 5) Knockout 
of Aph-1 sensitizes cells to apoptosis; 6), PS1 accounts for the majority of the -
secretase activity the PS1C299 (from amino acid 299 to the end amino acid 467) 
is the most active form of PS1 C. These new findings not only significantly 
contribute to our knowledge of the biochemistry of -secretase and its catalyzed 
Notch and APP processing, but also provide valuable information for the 
development of therapeutic strategy of prevention and treatment of AD.  
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INTRODUCTION  
 
Alzheimers’ Disease  
 
Dementia is a common brain disease, especially among aged people, from which 
not only patients but also their families deeply suffer. Among all kinds of 
dementia, about 50% to 70% are Alzheimer’s disease (AD). It has been more 
than 100 years since the description of the first AD case by the Germen 
psychiatrist Alois Alzheimer. However, there is still no cure available for 
treatment of this devastating disease. AD is a neurodegenerative disease which 
is clinically characterized by memory loss, inability of carrying conversation, 
impaired judgement, difficulty of recognizing people and eventually death 
(Alzheimer's 2013). As a progressive disease, it takes several years to develop 
which is emotionally, physiologically and financially consuming.  
Although age is recognized as the major risk factor of AD, AD is not a normal 
part of aging and more than 5 percent of AD patients have earlier onset (younger 
than 60). AD ranks as the sixth death cause in United States (Sherry et.al 2013), 
and even worse, the death caused by AD increase by 68% between 2000 and 
2010, while the death caused by other listed disease decreased (Arialdi et al 
2002 and Sherry et.al 2013). With the globally population ageing, AD will become 
a severe threaten with increasing shadows to people and our society.  
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Molecular Mechanism of AD 
Amyloid  Ahypothesis 
 
AD is pathologically characterized by the presence of extracellular plaques 
enriched in amyloid-beta (Aβ) peptides and intracellular neurofibrillary tangles 
containing hyperphosphorylated tau protein (Selkoe 1998). Mounting evidence 
suggests that the abnormal accumulation of Aβ is not only a hallmark of AD, but 
is a primary causative factor of AD, and this theory is known as amyloid 
hypothesis (Hardy and Selkoe 2002). Based on this hypothesis, it is believed that 
the accumulation of Ais the direct cause of AD, although, the amyloid 
hypothesis has and still does confront lots of doubts and rejections (Herrup 
2015). Another hallmark of AD is intracellular neurofibrillary tangles (NTFs), 
which are composed of phosphorylated tau protein. Together with extracellular 
plaque, NTFs were found in AD patient’s brain. Researchers have found that 
both NTFs and plaques could result in neuron loss which contributes dramatically 
to AD. However, compare to AaggregationNTFs is not the predominant one. 
Since the tangle formation could be influenced by both Aand APP, but the 
plaque formation is barely affected by tau overexpression, A is suggested to be 
the primary and deterministic factor of AD (Lewis, Dickson et al. 2001). 
Preclinical studies also support amyloid cascade hypothesis since 
Aimmunotherapies could help in preventing AD (Lemere and Masliah 2010). 
Therefore, amyloid cascade hypothesis is still the most widely accepted one in 
AD physiology.  
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APP processing and Aβproduction  
 
Aβ is produced from the amyloid precursor protein (APP). APP is a type I single 
transmembrane protein which could be processed in two different pathways: 
amyloidogenic pathway and non-amyloidogenic pathway. In these pathways, 
APP is first cleaved by -secretase or -secretase and produce C terminal 
fragments, CTFor CTFrespectively. The CTFand CTFwill be 
subsequently processed by -secretase into Aand p3, respectively and, 
concomitantly, a common APP intracellular C terminal domain (AICD) (Figure I) 
(Xu 2009). In fact, the first disease causative gene identified is the APP gene. 
The other two are Presenilin1 (PS1) and Presenilin 2 (PS2) genes. PS1 and PS2 
are two proteins sharing high homology with each other. Mutations in these two 
presenilin genes account for the majority of familial Alzheimer’s Disease (FAD) 
cases (De Strooper 2007). Interestingly, the mutations in all the disease 
causative genes, APP, PS1 and PS2, lead to one common consequence: the 
increased production of ABased on the accumulation of knowledge and 
evidences, amyloid cascade hypothesis was first summarized at the 1992 by Dr. 
Hardy and Dr. Higgins (Hardy and Higgins 1992). They suggest that the 
accumulation of Ais the direct cause of AD.  
BACE 
 
As mentioned above, A is produced from APP through sequential cleavage of 
secretase and secretase. secretase, also known as BACE (Beta Site 
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APP-Cleaving Enzyme) (Vassar, Bennett et al. 1999) has two homologues: 
BACE1 and BACE2, among which BACE1 has the major activity at processing 
APP and producing CTFwhich could be further processed into A (Farzan, 
Schnitzler et al. 2000, Basi, Frigon et al. 2003). BACE1 is confirmed of required 
for production of A through knock out experiments in mice (Cai, Golde et al. 
1993). The knockout of BACE in mice also cause dramatic neonatal lethality 
(Dominguez, Tournoy et al. 2005), which suggests that BACE is significantly 
necessary for some other functions in vivo.  This critical role of BACE in the 
development leads to the difficulties of targeting it for the treatment of AD. 
secretase components 
Further researches discovered that the ratio of Aβ42 versus Aβ40 (Aβ42/Aβ40) is 
critical for AD development (Hardy and Selkoe 2002, Kumar-Singh, Theuns et al. 
2006). The secretase controls the length of A. Therefore, secretase has 
come under the spotlight of AD research and for the understanding of 
mechanism of Aproduction and AD treatment. secretase is composed of at 
least four components: presenilins (PS1 or PS2), nicastrin (NCT), anterior 
pharynx-defective 1 (Aph-1), and presenilin enhancer 2 (Pen-2)  
Among those, the nine transmembrane protein presenilin (PS1 or PS2 isoforms) 
is thought to be the catalytic subunit, since the mutation of the two aspartyl 
residues results in the loss of secretase activity (Wolfe, Xia et al. 1999, Wolfe 
2002). NCT is suggested to be substrate receptor (Shah, Lee et al. 2005). A 
more recent research suggests NCT acts as a molecular gatekeeper for 
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substrate binding and catalysis through actively excludes larger substrates with 
steric hindrance (Bolduc, Montagna et al. 2016). Aph-1 might be required for the 
stabilization of other secretase components (Francis, McGrath et al. 2002, Lee, 
Shah et al. 2002, Steiner, Winkler et al. 2002). Pen-2 was believed to be required 
for the endoproteolysis of presenilin which is a necessary step in secretase 
maturation (Luo, Wang et al. 2003, Takasugi 2003). However, recent researches 
have raised questions to this notion, for example Pen-2 is only partially required 
for endoproteolysis of presenilin as demonstrated by recent studies (Mao, Cui et 
al. 2012, Holmes, Paturi et al. 2014) and NCT is not absolutely required for the 
processing of Notch which is one of secretase substrate (Zhao, Liu et al. 2010). 
These controversial results casted shadows over the current view regarding the 
functional role of each component in secretase complex. In addition, the 
catalytic functions of PS1 and PS2 have been well defined, however, the 
mechanisms remain elusive. Therefore, we set out to address these issues by 
the following proposed study.  
secretase substrates 
 
As discussed above, based on Amyloid hypothesis, one way for the treating AD 
is to inhibit secretase activity in order to reduce the production of Aβ. However, 
more than 90 type I transmembrane proteins have been identified as secretase 
substrates (Haapasalo and Kovacs 2011), including APP (De Strooper, Saftig et 
al. 1998), Notch (De Strooper, Annaert et al. 1999), E-cadherin, N-cadherin, 
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ErbB4 and so on. Specifically, secretase catalyzed Notch processing plays an 
important role in controlling cellular homeostasis and cell fate determination. 
Thus, it becomes difficult to simply inhibit secretase activity as a therapeutic 
strategy for treating AD. Notch pathway requires the processing of secretase to 
produce a Notch intracellular domain (NICD) in order to regulate the transcription 
of important genes for cell development, proliferation, differentiation and so on 
(Kopan and Ilagan 2009, Andersson, Sandberg et al. 2011). Thus, the inhibition 
of secretase will result in other severe consequences through failure of Notch 
signaling regulation. Therefore, it becomes important to find a way to selectively 
inhibit secretase catalyzed APP processing without affecting the Notch 
processing, which is one of the goals of my research project.  
Apoptosis in AD 
 
The importance of apoptosis in AD has been discussed in 1998 by Marcia 
Barinaga (Barinaga 1998), in which they speculate that apoptosis could play a 
role in neuron death found in AD. Since then, scientists found more evidence to 
support this idea. The anti-apoptotic protein level Bcl2 was found lower in AD 
brain, the active forms of caspase 3 was detected and so does the fragmentation 
of DNA (Shimohama 2000). In vitro experiments have also demonstrated that 
expression of Aβ could induce the activation of caspases (Ivins, Thornton et al. 
1999). Lots of signaling pathway, like JNK (Troy, Rabacchi et al. 2001), GSK3β 
(Lucas, Hernandez et al. 2001), even PS1 (Soriano, Kang et al. 2001) itself have 
been reported of involving in the apoptosis of AD (Bamberger and Landreth 
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2002). Besides PS1, some other secretase components, like Aph-1 and Pen-2 
have been found contribute to apoptosis as protective roles through p53 pathway 
due to the fact that they could help in keeping the integrity of secretase 
complex (Dunys, Kawarai et al. 2007). Since we have different secretase 
components knock out cells, alongside with investigations about their roles in 
secretase activity, we also studies their role in apoptosis. Our result 
demonstrates that the knock out Aph-1 lead to higher tendency of apoptosis in 
mouse embryonic fibroblast (MEF) cells when triggered by MG132 through Akt-
GSK3β pathway. Combined with the results of secretase activity: Aph-1 is not 
definitely required for the processing of both Notch and APP, but more 
importantly for the stability of secretase and cell survival (Hu, Zeng et al. 2015). 
Therefore, the targeting of Aph-1 in treating AD is completely unreasonable 
theoretically.  
Therapy 
 
Several anti-Aβ monoclonal antibodies like Bapineuzumab and crenezumab were 
tested in clinical trials. They have been demonstrated to have no significant effect 
on cognition but only decrease some level of aggregated Aβ or soluble Aβ 
(Doody, Thomas et al. 2014, Salloway, Sperling et al. 2014). Some β-secretase 
inhibitors are under test at the clinical trial phase 2 or 3. They have been found to 
be able to reduce 80% production of Aβ, but the effects on cognition and 
prevention of AD need to be further determined (Ayutyanont, Langbaum et al. 
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2014) (Bateman 2015). Lots of secretase inhibitors (GSI) and secretase 
modulators (GSM) are at phase 2 or 3 stage of clinical trials, but most of them 
are either not efficient or have significant side effects and toxicity since including 
Notch, plenty of secretase substrates and their pathways are influenced 
(Cummings 2010, Samson 2010, Schor 2011). When comparing with GSI, the 
toxicity of GSM is much less since they only regulate the length of Aβ rather than 
the activity of secretase. Since the longer forms of Aβ have been demonstrated 
to be easier at aggregation and forming plaque (Xu 2009), if proper GSM which 
could reduce the production of longer Aβ, that would be helpful in treat AD. 
Alternatively, we might be able to switch to targeting secretase components, 
for example NCT, since we have found that the knockout of NCT could 
selectively inhibits APP processing, but has less effect on Notch processing (Hu, 
Zeng et al. 2015). Hope our research on the structure and function of secretase 
could provide further supports on the development of AD treatment.  
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CHAPTER I 
 
NICASTRIN IS REQUIRED FOR APP BUT NOT 
NOTCH PROCESSING, WHILE APH-1 IS 
DISPENSABLE FOR PROCESSING OF BOTH APP 
AND NOTCH 
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Abstract  
  
The -secretase complex is composed of at least four components: presenilin 
(PS1 or PS2), nicastrin (NCT), anterior pharynx-defective 1 (Aph-1), and 
presenilin enhancer 2 (pen-2). In this study, using knockout cell lines, our data 
demonstrated that knockout of NCT, as well as knockout of Pen-2, completely 
blocked -secretase-catalyzed processing of CTFα and CTFβ, the C-terminal 
fragments of β-amyloid precursor protein (APP) produced by α-secretase and β-
secretase cleavages, respectively. Interestingly, in Aph-1-knockout cells CTFα 
and CTFβ were still processed by -secretase, indicating Aph-1 is dispensable 
for APP processing. Furthermore, our results indicate that Aph-1 as well as NCT 
is not absolutely required for Notch processing, suggesting that NCT is 
differentially required for APP and Notch processing. In addition, our data 
revealed that components of the -secretase complex are also important for 
proteasome- and lysosome-dependent degradation of APP and that endogenous 
APP is mostly degraded by lysosome while exogenous APP is mainly degraded 
by proteasome. 
Introduction 
 
    One of the hallmarks of Alzheimer's disease (AD) is the abnormal production 
and accumulation of β-amyloid peptide (Aβ) in the brain. According to the 
amyloid hypothesis, the ratio of the long Aβ species, Aβ42, versus the short 
Aβ40 (Aβ42/Aβ40) has been considered to play a critical role in AD (Hardy and 
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Selkoe 2002). An increased Aβ42/Aβ40 ratio appears to correlate with early-
onset familial AD cases caused by presenilin mutations (Kumar-Singh, Theuns et 
al. 2006). Aβ is derived from the amyloid precursor protein (APP) by successive 
action of the β- and -secretases. APP can be processed via two pathways, the 
non-amyloidogenic pathway or the amyloidogenic pathway. In the non-
amyloidogenic pathway, APP is first cleaved by -secretase to release a soluble 
N-terminal ectodomain and a membrane anchored C-terminal fragment (CTF); 
in the amyloidogenic pathway, APP is first cleaved by β-secretase to remove the 
N-terminal fragment and generate a membrane-anchored C-terminal fragment of 
APP (CTF). Both CTF and CTF are then subsequently cleaved within the 
transmembrane domain by -secretase to produce a common APP intracellular 
domain (AICD) and lead to the generation of a p3 fragment from CTF and the 
full-length A from CTF (Xu 2009). Since the -secretase-catalyzed cleavage 
determines the C-termini of A species and the ratio of Aβ42/Aβ40, dissecting 
the biological and biochemical nature ofsecretase is important for 
understanding the mechanism of Aβ formation. Thus far at least four 
polypeptides have been identified as necessary components for -secretase 
activity (Dries and Yu 2008, Zhang, Li et al. 2014). These four components are 
presenilins (PS1 or PS2), nicastrin (NCT), anterior pharynx-defective 1 (Aph-1), 
and presenilin enhancer 2 (Pen-2). Mutation of the two conserved aspartyl 
residues in PS1 and PS2 results in the loss of -secretase activity (Wolfe 1999), 
and affinity labeling experiments have demonstrate that -secretase inhibitors 
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bind directly to PS1 (Esler, Kimberly et al. 2000, Li, Xu et al. 2000); therefore, the 
nine transmembrane protein presenilin (PS1 or PS2 isoforms) is thought to 
function as the catalytic subunit of -secretase (Wolfe 2002). The identification of 
a substrate-binding domain in NCT strongly suggests that NCT functions as the 
substrate receptor (Shah, Lee et al. 2005). Using siRNA technology, studies 
suggested that the seven transmembrane protein Aph-1 is required for 
stabilization of the PS1 endoproteolysis products PS1N and PS1C (Francis, 
McGrath et al. 2002, Lee, Shah et al. 2002, Steiner, Winkler et al. 2002) and that 
the two transmembrane protein Pen-2 is required for endoproteolysis of PS1 
(Luo, Wang et al. 2003, Takasugi, Tomita et al. 2003). However, recent studies 
have shown that Pen-2 is dispensable for endoproteolysis of PS1 (Mao, Cui et al. 
2012, Holmes, Paturi et al. 2014). One study also showed that NCT is not 
absolutely required for -secretase activity (Zhao, Liu et al. 2010). To further 
determine the role of each component of the -secretase complex in -secretase 
activity, we used knockout cell lines to examine the effect of deletion of each 
component on the processing of CTFα and CTFβ. Our data demonstrated that 
knockout of Pen-2, as well as NCT, almost completely blocked the processing of 
both CTFα and CTFβ. However, knockout of Aph-1 had no significant effect on 
the processing of CTFα and CTFβ, indicating Aph-1 is dispensable for APP 
processing. Furthermore, our results revealed that NCT is differentially required 
for -secretase-catalyzed processing of APP and Notch. In addition, our data 
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suggest that the components essential for -secretase-dependent APP 
processing are also important for APP degradation. 
Materials and Methods 
 
Cell culture 
 
Mouse embryonic fibroblast (MEF) cells established from PS1/PS2-double 
knockout (PS1/2-/-) cells (Herreman, Serneels et al. 2000), PS1-knockout (PS1-/-) 
cells (De Strooper, Saftig et al. 1998), PS2-knockout (PS2-/-) cells (Herreman, 
Hartmann et al. 1999), Pen-2-Knockout (Pen-2-/-) cells (Bammens, Chavez-
Gutierrez et al. 2011), and wild-type mouse embryonic fibroblasts were all kindly 
provided by Dr. Bart De Strooper (Center for Human Genetics, Belgium). 
Nicastrin-knockout (NCT-/-) cells (Li, Ma et al. 2003) and Aph-1abc-triple-deficient 
(Aph-1-/-, deficient in all three Aph-1a, Aph-1b, and Aph-1c isoforms) cells 
(Chiang, Fortna et al. 2012) were kindly provided by Dr. Tong Li (John Hopkins 
University). The wt-7 cells (N2a cells stably expressing wild-type presenilin 1 
[PS1wt] along with Swedish mutant APP [APPsw]) were kindly provided by Drs. 
Sangram S. Sisodia and Seong- Hun Kim (University of Chicago). All cells were 
cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine 
serum, 2 mM L-glutamine (Lonza, Walkersville, MA, USA), 100 units/mL penicillin 
(Lonza), and 100 μg/mL streptomycin (Lonza).  
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Inhibitors and reagents 
 
Proteasome inhibitor MG132 was purchased from Peptides International 
(Louisville, KY, USA). Gamma-secretase inhibitors compound E and L685, 458 
and proteasome inhibitor lactacystin were purchased from EMD Millipore 
(Billerica, MA, USA). Lysosome inhibitors chloroquine, leupeptin, and NH4Cl were 
purchased from Sigma (St. Louis, MO, USA). The general caspase inhibitor, 
benzyloxycarbonyl-Val- Ala-Asp-fluoromethylketone (Z-VAD-fmk) was purchased 
from Enzo Life Sciences (Farmingdale, NY, USA). Complete protease inhibitor 
cocktail tablets were purchased from Roche Applied Science (Indianapolis, IN, 
USA). Lipofectamine LTX with plus reagent was purchased from Invitrogen 
(Carlsbad, CA, USA).  
Antibodies 
 
Anti-PS1C, anti-NICD (#4147, which specifically recognizes the processed 
Notch), anti-caspase3, and anti-caspase-6 were purchased from Cell Signaling 
(Danvers, MA). Anti-NCT was from Sigma-Aldrich (St. Louis, MO, USA). 
Polyclonal antibodies anti-Aph-1aL and anti-PEN-2N were from Covance 
(Princeton, NJ, USA). Anti-Aph-1bc was from NOVUS (Littleton, CO, USA). 
Polycolonal antibody C15 was raised against the last 15 amino acids at the very 
C terminal of APP (Zhao, Mao et al. 2004). Anti-myc antibody, C-Myc (9E10), 
was purchased from Santa Cruz (Dallas, TX, USA). Anti-GAPDH (glyceraldehyde 
3-phosphate dehydrogenase) was from EMD Millipore.  
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Plasmids 
 
Plasmid expressing the truncated ectodomain and myc-tagged Notch molecule 
(NotchΔE) containing the murine Notch-1 leader peptide (1-23 amino acids) 
(Kopan, Schroeter et al. 1996) was kindly provided by Dr. Raphael Kopan 
(Washington University) and Dr. Masayasu Okochi (Osaka University, Japan). 
The plasmid APPsw, which expresses a C-terminal myc-tagged Swedish mutant 
APP (APPsw) (Thinakaran, Teplow et al. 1996), was kindly provided by Dr. 
Gopal Thinakaran (University of Chicago). 
Reverse transcription-polymerase chain reaction (RT-PCR) 
 
RT-PCR was carried out as described previously (Hao, Tan et al. 2010). Total 
RNA was isolated from MEF cells mentioned above using an RNeasy mini-prep 
kit (Qiagen, Hilden, Germany). cDNA was synthesized from 2 μg total RNA using 
the ThermoScipt RT-PCR kit (Invitrogen). The cDNA products were amplified 
using GeneAmp PCR core reagents (Applied Biosystems, Foster City, CA, USA) 
and a Stratagene Mx3000P thermocycler (Agilent, Santa Clara, CA, USA) with 
the following program: 5 min at 95°C followed by 28 cycles of denaturing at 95°C 
for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 45 s followed by a 
final extension for 7 min at 72°C. The primers used were as follows: Aph-1a, 
forward 5′-ACGGAAGATCACCCAT-3′ and reverse 5′-
TGTCAGAAGGTGACTCCCA-3′; Aph-1b,c, forward 5′-
CCTGACGCATCTGGTGGTG-3′ and reverse 5′-GTTCCAAGATACAGGGG-3′; 
and NCT, forward 5′-TCTTCTCACACATGCACGCC-3′ and reverse 5′-
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CATGGGATCTGTGTGCATCC-3′. The PCR products were analyzed by 
electrophoresis on a 2% agarose gel.  
Enzyme-linked immunosorbent assay (ELISA) 
 
ELISA was performed as described previously (Tan, Mao et al. 2008, Zhao, Liu 
et al. 2010). MEF cells were cultured for 24 h. Conditioned media (CM) were 
supplemented with an inhibitor cocktail (Millipore) containing AEBSF (4-[2-
aminoethyl] benzenesulfonyl fluoride hydrochloride) at a final concentration of 1 
mM. The CMs were analyzed with a mouse Aβ40-
according to the manufacturer’s instructions.  
Cell-free assay 
 
In vitro AICD (APP intracellular domain) generation was determined by cell-free 
assay using the protocol reported by Tesco et al (Tesco, Ginestroni et al. 2005). 
MEF cells were grown at a density of 150,000 cells/cm2 for 24 h. Cells were 
scraped in 1 ml buffer A (50 mM HEPES, 150 mM NaCl, 5 mM 1,10-
phenanthroline monohydrate [PNT], pH=7.4) and homogenized by passing them 
through 25-gauge 5/8 needles 10 times. The homogenate was centrifuged at 
10,000 × g for 15 min at 4°C. The membrane fraction obtained was washed once 
with buffer A and centrifuged at 10,000 × g for 5 min at 4℃. Total protein was 
measured in the membrane fraction, and protein aliquots were incubated with 50 
µl buffer B (50 mM HEPES, 150 mM NaCl, 5 mM PNT, cocktail protease 
inhibitor, chloroquine (10 μM), pH=7.0) for 2 h at 37°C in the presence or 
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absence of L685, 458 to induce the production of AICD. After incubation, 
samples were centrifuged at 10,000 × g for 15 min at 4°C. The supernatants 
were collected and analyzed by Western blot using anti-APP-CTF antibody, C15.  
SDS-PAGE and Western blotting 
 
For analysis of endogenous APP processing, 10 h after splitting, cells were 
incubated overnight in the presence or absence of the following inhibitors 
compound E (5nM), L685, 458 (0.5 μM), lactacystin (10 μM), MG132 (5uM), 
chloroquine (10 μM), leupeptin (5 μg/ml), and NH4Cl (1mM). For analysis of the 
exogenous APP and Notch processing, the cells, 24 h after splitting, were 
transfected with plasmids expressing APPsw or NotchΔE with lipofectamine LTX. 
Ten hours after transfection, inhibitors were added and the cells were further 
incubated overnight. Cell lysis and Western blot analysis were carried out as 
described previously (Zhao, Mao et al. 2004). Briefly, cells were lysed with 
sonication for 20 s on ice in Western blot lysis buffer (50 mM Tris–HCl, pH 6.8, 
8 M urea, 5% mercaptoethanol, 2% SDS, and protease inhibitor mixture). After 
addition of 4 × SDS sample buffer and boiling at 100°C for 7 min, samples were 
subjected to SDS-polyacrylamide gel electrophoresis (SDS PAGE, 16% for APP 
CTFs; 14% for PS1 C terminals, caspases, and GAPDH; 10% for Notch and C-
Notch; 6% for APP). The membranes were probed with appropriate antibodies as 
described in figure legends.  
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Statistical analysis 
 
Data are expressed as mean ± SEM and assessed for significance by Student's t 
test. When P > 0.05, differences were considered not significant. 
All methods used are approved by University of Tennessee (Registration #309-
13). 
Results 
 
Aph-1 is dispensable for -secretase-catalyzed processing of CTF 
 
To determine the role of the components of the -secretase complex in APP 
processing activity, we examined the effects of deletion of each component of the 
complex on the processing of CTF. As shown in Figure 1. 1a, as expected, in 
the absence of inhibitor, almost no CTF was detectable in wild type (wt) cells 
(lane 9). However, when the cells were treated with transition state -secretase 
inhibitor L-685,458, a significant amount of unprocessed CTF was accumulated 
(lane 10). As reported previously (Herreman, Serneels et al. 2000), a dramatic 
accumulation of unprocessed CTF was observed in the PS1 and PS2 double 
knockout (PS1/2-/-) cells (compare lanes 13 and 14) regardless of the presence 
or absence of -secretase inhibitor. Similarly, significant accumulation of CTF 
was also observed in nicastrin-knockout (NCT-/-) cells (lanes 3 and 4) and Pen-2-
knockout (Pen-2-/-) cells (lanes 5 and 6) regardless of the presence or absence of 
-secretase inhibitor.  
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However, in contrast to knockout of NCT or Pen-2, a significant decrease in 
the level of CTF was detected in the Aph-1-knockout (Aph-1-/-) cells in which all 
three murine Aph-1 alleles–termed Aph-1a, Aph-1b, and Aph-1c–were knocked 
out (Figure 1. 1a, lane 1). More interestingly, the decrease in the level of CTF 
was completely blocked by -secretase inhibitor (lane 2). In addition, we also 
observed that knockout of PS2 had almost no effect on the turnover of CTFα 
(lane 11) and this decrease in CTFα in PS2-knockout (PS2-/-) cells was 
completely inhibited by -secretase inhibitor (lane 12). This result indicates that 
knockout of PS2 did not cause significant reduction in -secretase activity. 
However, a significant amount of CTFα was detected in the PS1-knockout (PS1-/-
) cells in the absence of inhibitor (lane 7), indicating a substantial reduction in -
secretase activity.  
Previous studies have reported that CTFs of APP undergo degradation by a 
proteasome-dependent mechanism distinct from -secretase (Skovronsky, Pijak 
et al. 2000, Nunan, Shearman et al. 2001, Nunan, Williamson et al. 2003). To 
determine whether the decrease of CTF detected in the Aph-1-knockout cells is 
indeed due to -secretase, we examined the effect of proteasome inhibitor on the 
turnover of CTFAs shown in Figure 1. 1b, treatment of cells with proteasome 
inhibitor MG132 caused a slight increase in the level of CTF in Aph-1-1- cells 
(compare lane 2 with lane 1). A similar result was also observed in PS1-knockout 
cells (compare lane 8 with lane 7) and wt cells (compare lane 14 with lane 13). 
However, the extent of the increase in CTF caused by MG132 is much less 
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than that caused by -secretase inhibitor (compare Figure 1. 1b with 1a). These 
results indicate that, similar to wt cells, the turnover of CTF in the Aph-1-/- cells 
is mainly catalyzed by -secretase activity. In addition, MG132 showed no 
significant effect on the level of CTF in NCT-/- cells (compare lanes 4 with lane 
3), Pen-2-/- cells (compare lane 6 with lane 5), nor PS1/2-/- cells (compare lane 12 
with lane 11). It was noted that no CTFβ was detected in these experiments, 
suggesting a possibility that the mouse endogenous APP was mostly processed 
via the α-secretase pathway and that the low level of CTFβ was undetectable 
under our experimental conditions.  
If the turnover of CTFα in Aph-1-/- cells were catalyzed by -secretase activity 
rather than by random degradation, the AICD produced by -secretase activity 
would be detectable. However, AICD was not detected in the experiments shown 
in Figure 1. 1a and b, possibly due to rapid degradation of this peptide in living 
cells [Cupers, 2001 #7150]. Thus, we performed a cell-free assay using the 
procedure described previously (Tesco, Ginestroni et al. 2005). As shown in 
Figure 1. 1c, in the absence of -secretase inhibitor, a significant amount of AICD 
was readily detected in membrane prepared from wt (lane 5), Aph-1-/- (lane 7), 
and PS2-/- (lane 9) cells, and the generation of AICD in these cells was strongly 
inhibited by -secretase inhibitor L-685,458 (lanes 6, 8, and 10). Similarly, in wt-7 
cells, both AICD-myc and AICDendo, produced from exogenous APP with a myc-
tag and endogenous APP, respectively, were detected at very high levels (lane 
15) and inhibited by L-685,458 (lane 16). However, this AICD was not detected in 
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NCT-/-, Pen-2-/-, and PS1/2-/- cells regardless of the presence or absence of -
secretase inhibitor (lanes 1 to 4, and lanes 13 and 14). These results strongly 
indicate that the turnover of CTFα in Aph-/- cells is catalyzed by -secretase 
activity. AICD was hardly detected in PS1-/- cells (lanes 11 and 12), suggesting 
that PS1 accounts for the majority of the -secretase activity. To further ascertain 
whether APP is indeed processed by -secretase in Aph-1-/- cells, we performed 
an ELISA to determine the formation of Aβ in these cells. As shown in Figure 1. 
1d, a large amount of Aβ40 was detected in the media of wt and PS2
-/- cells. 
Interestingly, a significant amount of Aβ40 (> 50% of that detected in wt cells) was 
also detected in Aph-1-/- cells when PS1/2-/- cells were used as a negative 
control. This result provided further strong support to the notion that APP is 
indeed processed by -secretase activity in Aph-1-/- cells. On the other hand, only 
a low, but still significant, level of Aβ40 (< 20% of that detected in wt cells) was 
detected in PS1-/- cells, and a very low level of Aβ40 (< 8% of that detected in wt 
cells) was also detected in NCT-/- and Pen-2-/- cells. 
Aph-1c protein is undetectable in Aph-1abc-triple deficient cells under the 
experimental conditions 
Since the Aph-1-/- cells were created by knockdown of Aph-1c in Aph-1a/b 
double knockout cells using shRNA technology (Chiang, Fortna et al. 2012), one 
concern is whether the -secretase activity detected in Aph-1-/- cells results from 
incomplete knockdown of Aph-1c. To address this issue, we performed a RT-
PCR assay to determine the mRNA level of Aph-1c using primers corresponding 
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to the coding regions of Aph-1c. As controls, similar RT-PCR was also performed 
for Aph-1a and NCT. As shown in Figure 1. 1e, as expected, neither NCT mRNA 
nor Aph-1a mRNA was detected in NCT-/- and Aph-1-/- cells, respectively. 
However, as shown in the second panel of Figure 1. 1e, a fine PCR band was 
detected in Aph-1-/- cells, indicating the presence of a trace amount of residual or 
partially cleaved Aph-1c mRNA in Aph-1-/- cells. Thus, we further determined the 
protein levels of Aph-1c and other components in these knockout cells used. As 
shown in Figure 1. 1f, Western blot analysis using specific antibodies confirmed 
the absence of PS1, PS2, NCT, and Pen-2 as well as Aph-1 (Aph-1a, Aph-1b, 
and Aph-1c) proteins in the corresponding knockout cells. Specifically, the fact 
that antibody specific to Aph-1b/c did not detect any signal in Aph-1-/- cells 
suggests that the Aph-1c gene was efficiently silenced by shRNA technology.  
Components of the -secretase complex might also play a role in regulating 
APP CTF degradation by proteasome and lysosome.  
It was noted from the above experiments that treatment with proteasome inhibitor 
MG132 caused an increase in the level of CTF in wt, Aph-1-/-, and PS1-/- cells. 
However, MG132 showed no effect on the level of CTF in NCT-/-, Pen-2-/-, and 
PS1/2-/- cells. These results suggest that knockout of different components might 
have different effects on the proteasome-dependent turnover of CTFα. APP and 
its processing products have also been reported to be subjected to lysosome 
degradation (Eisele, Baumann et al. 2007, Vingtdeux, Hamdane et al. 2007). 
Thus, next, we examined the effects of other proteasome and lysosome inhibitors 
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on the turnover of CTFα in these knockout cells. As shown in lanes 2 and 3 of the 
top four panels of Figure 1. 2a, as expected, both of the -secretase inhibitors, 
compound E (compE) and L-685,458, caused accumulation of unprocessed 
CTFα in wt, PS1-/-, PS2-/-, and Aph-1-/- cells. When the cells were treated with 
proteasome inhibitors MG132, strong accumulation of CTFα resulted in wt, PS1-/-
, and Aph-1-/- cells (lane 5), but lactacystin in comparison, caused a lesser 
accumulation of CTFα in PS1-/- and Aph-1-/- cells (lane 4), and CTFα was hardly 
detectable in wt cells (lane 4). Neither MG132 nor lactacystin had a detectable 
effect on the CTFα level in PS2-/- cells (Panel 3, lanes 4 and 5). When the cells 
were treated with the lysosome inhibitors chloroquine, leupeptin, and NH4Cl, 
significant accumulation of CTFα was observed in wt, PS1-/-, PS2-/-, and Aph-1-/- 
cells. In addition, it was noted that in the presence of lysosome inhibitors, 
specifically, chloroquine and leupeptin, the APP intracellular c-terminal domain 
(AICD) produced by -cleavage of CTFα become detectable in wt cells, PS2-/- 
cells, and to a lesser extent in Aph-1-/- cells. These results suggest that lysosome 
is the major site for CTFα degradation. In addition, the detection of AICD in the 
presence of lysosome inhibitors indicates that these lysosome inhibitors have no 
effect on -secretase catalyzed processing of CTFα. As shown in the bottom 
three panels of Figure 1. 2a, the proteasome inhibitors lactacystin and MG132 
had no effect on the level of CTFα in PS1/2-/-, NCT-/-, and Pen-2-/- cells. 
Lysosome inhibitors caused a slight increase in the level of CTFα in these cells. 
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These results indicate that CTFα was not significantly degraded by either 
proteasome or lysosome activity in these cells.  
As mentioned above, possibly because mouse endogenous APP was mostly 
processed via the α-secretase pathway, the level of endogenous CTFβ was too 
low to be detected under our experimental conditions. To determine the effects of 
knockout of each -secretase component on the processing of CTFβ, we 
transiently transfected these cells with a plasmid expressing myc-tagged human 
Swedish mutant APP (APPsw) in the presence or absence of different inhibitors. 
As shown in Figure 1. 2b, recombinant APP was detected in all transfected cells. 
As shown in the top panel, in the wild type-cells, endogenous CTFα 
(CTFα[endo]) as well as CTFα-myc and CTFβ-myc produced from exogenous 
myc-tagged APPsw, were accumulated in the presence of the -secretase 
inhibitors compound E (lane 4) and L-685,458 (lane 5). Similarly, -secretase 
inhibitors caused accumulation of unprocessed CTFα-myc, and CTFα(endo) was 
also clearly detected in Aph-1-/-, PS2-/-, and PS1-/- cells. These results indicate 
that -secretase inhibitors had similar effects on both exogenous and 
endogenous APP in these cells, excepting that CTFβ-myc was hardly detected in 
these cells. In wt cells, the accumulation of CTFα(endo), CTFβ-myc, and CTFα-
myc was also detected when cells were treated with the lysosome inhibitors 
chloroquine and leupeptin, and to a lesser extent with NH4Cl (lanes 8–10). 
However, mainly CTFα-myc and CTFβ-myc, but almost no CTFα(endo), were 
accumulated in the presence of proteasome inhibitors lactacystin (lane 6) and 
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MG132 (lane 7). In PS1-/-, PS2-/-, and Aph-1-/- cells, both CTFα(endo) and CTFα-
myc were detected at various levels in the presence of these proteasome and 
lysosome inhibitors. However, almost no CTFβ-myc was detected in these cells, 
with the exception of MG132-treated Aph-1-/- cells (fourth panel, lane 7). A small 
amount of CTFα-myc was detected in PS1-/- cells in the absence of any inhibitors 
(second panel, lane 3), indicating a low -secretase activity in these cells in 
comparison with that in PS2-/- cells.  
It was interestingly noted that in PS1-/-, PS2-/-, and Aph-1-/- cells, treatment 
with proteasome inhibitors lactacystin and MG132 mainly caused accumulation 
of CTFα-myc (Figure 1. 2b, lanes 6 and 7), whereas lysosome inhibitors mostly 
caused accumulation of CTFα(endo) (lanes 8–10). These data revealed an 
interesting finding that exogenous APP was primarily degraded by proteasome, 
and the endogenous APP was mostly degraded by lysosome. This notion was 
further supported by the fact that exogenous full-length APP (both mature and 
immature forms) was detected at high levels in the presence of proteasome 
inhibitors in all cells (lanes 6 and 7). In contrast to the PS1-/-, PS2-/-, and Aph-1-/- 
cells, neither proteasome nor lysosome inhibitors had a significant effect on the 
levels of CTFα(endo) and CTFα-myc in PS1/2-/- cells (fifth panel), NCT-/- cells 
(sixth panel), nor Pen-2-/- cells (seventh panel), indicating that APP CTFs were 
not significantly degraded by these organelles in these cells. A small amount of 
CTFβ-myc was also detected in these cells, specifically in cells treated with 
MG132 and lysosome inhibitors (lanes 7–10). The above results clearly indicate 
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that the effects of proteasome and lysosome on the turnover of full-length APP 
and APP CTFs vary in different knockout cells. 
-secretase-catalyzed CTFprocessing in Aph-1-/- cells is independent of 
proteasome and lysosome activity 
Data presented in Figure 1. 2a show that AICD was detected in Aph-1-/- cells as 
well as in wt and PS2-/- cells in the presence of lysosome inhibitors, indicating 
that -secretase activity was not affected by these lysosome inhibitors. In other 
words, -secretase-catalyzed processing of CTFα is independent of lysosome 
activity in these cells. To further determine whether the -secretase inhibitors 
compound E and L-685,458 caused accumulation of CTFα in Aph-1-/- cells was 
not due to inhibition of proteasome or lysosome activity, we performed the 
following experiments. As shown in Figure 1. 3a, the amount of CTFα 
accumulated in cells treated with both compound E and MG132 (lane 7) was 
roughly the sum of the CTFα detected in cells treated with compound E (lane 2) 
and MG132 (lane 4), separately. A similar result was also observed when L-
685,458 was used in combination with MG132 compared with L-685,458 and 
MG132 alone (compare lane 9 with lanes 3 and 4). During the course of the 
experiments, it was noted that treatment with MG132 could induce the activation 
of caspase, which has been implied in the turnover of APP CTFs (Weidemann, 
Paliga et al. 1999). This raised the question as to whether inhibition of caspase 
activation would lead to further accumulation of CTFα in cells treated with 
MG132. Indeed, a greater amount of CTFα was observed in MG132-treated cells 
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in the presence of pan caspase inhibitor Z-VAD (compare lane 6 with lane 4). 
When these cells were further treated with compound E, an even greater amount 
of CTFα was accumulated (compare lane 8 with lane 6). A similar result was also 
observed when L-685,458 was added with MG132 and Z-VAD (compare lane 10 
with lane 6). These results indicate that -secretase inhibitor and proteasome 
inhibitor have an additive effect on the accumulation of unprocessed CTFα 
through different mechanisms. Furthermore, it was noted that in addition to 
regular PS1C produced by normal endoproteolytic processing of PS1, a short C-
terminal fragment of PS1, CaspPS1C, which was produced by caspase activity 
(Zeng, Hu et al. 2015), was detected in cells treated with MG132 (lanes 4, 7, and 
9), and the formation of CaspPS1C was completely inhibited by the addition of 
pan caspase inhibitor Z-VAD (lanes 6, 8, and 10).  
Next, we examined the additive effect of -secretase inhibitors and lysosome 
inhibitors on the accumulation of unprocessed CTFα. As shown in Figure 1. 3b, 
the amount of CTFα accumulated in the cells treated with both compound E and 
chloroquine (lane 6) was roughly the sum of the CTFα detected in cells treated 
with compound E (lane 2) and chloroquine (lane 4), separately. A similar result 
was also observed when cells were treated with L-685,458 and chloroquine 
(compare lane 7 with lanes 3 and 4). Likewise, leupeptin exhibited a similar 
additive effect on CTFα accumulation when used in combination with compound 
E (compare lane 8 with lanes 2 and 5) and L685, 458 (compare lane 9 with lanes 
3 and 5). These data indicate that -secretase inhibitor-caused accumulation of 
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CTFα in Aph-1-/- cells is not due to inhibition of proteasome or lysosome, i. e., -
secretase-catalyzed CTFα processing in Aph-1-/- cells is independent of 
proteasome and lysosome activity.  
Aph-1, as well as nicastrin is, dispensable for -secretase-catalyzed 
processing of Notch 
Data presented above demonstrate that Aph-1 is not absolutely required for -
secretase-catalyzed APP CTF processing, while NCT and Pen-2 are crucially 
essential for this process. In addition to APP, Notch is another well-characterized 
substrate of -secretase. We next examined the effect of knockout of different 
components of the -secretase complex on the processing of Notch. To do so, 
cells were transfected with a plasmid expressing NotchΔE, the ectodomain-
truncated and myc-tagged Notch containing the murine Notch-1 leader peptide 
(1-23 amino acids) (Kopan, Schroeter et al. 1996) in the presence or absence of 
-secretase inhibitor L-685,458. As shown in Figure 1. 4a, recombinant NotchΔE 
was detected with anti-myc antibody at various levels in wild-type and knockout 
cells, possibly due to different transfection efficiency. As shown in the middle 
panel, NICD, which is produced by -secretase from NotchΔE, was detected in 
wild-type cells (lane 13), PS2-/- cells (lane 9), and PS1-/- cells (lane 7), Aph-1-/- 
cells (lane 1), and NCT-/- cells (lane 3), and the formation of this NICD was 
strongly inhibited by the addition of L-685,458 (lanes 2, 4, 8, 10, and 14). 
However, this NICD was not detected in PS1/2-/- cells (lane 11) nor Pen-2-/- cells 
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(lane 5). These results revealed an interesting finding that, under our 
experimental conditions, NCT is crucially essential for -secretase-catalyzed APP 
CTFs processing, but is not absolutely required for -secretase-catalyzed Notch 
processing.  
Generation of NICD from NotchΔE is not affected by proteasome and 
lysosome inhibitors 
Data presented in Figure 1. 2 demonstrate that CTFα was also degraded by 
proteasome and lysosome in a -secretase-independent mechanism. Next, we 
determined whether Notch is also subjected to proteasome and/or lysosome 
degradation and whether proteasome and lysosome inhibitors have any effect on 
NICD formation. As shown in the middle panel of Figure 1. 4b, -secretase 
inhibitors compound E (lane 4) and, specifically, L-685,458 (lane 5) strongly 
inhibited the formation of NICD from NotchΔE. However, the level of NICD in 
proteasome inhibitors-treated cells was slightly increased (lanes 6 and 7), likely 
due to the protection of NICD from degradation, while the lysosome inhibitors 
showed no effect on the generation of NICD (lanes 8–10). In addition, the level of 
unprocessed NotchΔE was also slightly increased in proteasome inhibitor-treated 
cells (top panel, lane 6 and 7), suggesting that, though to lesser extent, NotchΔE 
also underwent proteasome degradation. Taking together, these data suggest 
that both NotchΔE and NICD undergo proteasome degradation, but the 
proteasome and lysosome inhibitors have no effect on -secretase-catalyzed 
processing of Notch. 
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Recovery of PS1C does not necessarily restore the -secretase activity 
toward APP in NCT-/- cells. 
Previous study revealed that Pen-2, Aph-1, and NCT are not necessary for 
endoproteolytic processing of PS1, but are required for stabilization of the PS1 
endoproteolytic processing products PS1N and PS1C (Mao, Cui et al. 2012). 
Thus, it is speculated that the loss of -secretase activity toward CTFα and CTFβ 
might have resulted from the instability of endoproteolytic products of PS1 in 
NCT-/- and Pen-2-/- cells. As shown in the top panel of Figure 1. 5, in the absence 
of MG132, PS1C was detected in wt cells (lane 9), in PS2-/- cells (lane 5), and, to 
a lesser but significant extent, in Aph-1-/- cells (lane 1). A very low level of PS1C 
was detected in NCT-/- cells at (lane 3), and only a trace amount of PS1C was 
detected in Pen-2 cells (lane 7). As expected, no PS1C was detected in PS1-/- 
cells (lane 11). This result confirmed again that Pen-2 is crucial for stabilizing 
PS1C. This result also revealed that Aph-1 is less important for stabilizing the 
endoproteolytic products of PS1.  
When the cells were treated with MG132, a significant decrease in the level of 
PS1C and a concomitant significant increase in the level of CaspPS1C produced 
by caspase activity were detected in wt cells (lane 10), PS2-/- cells (lane 6), and 
Aph-1-/- cells (lane 2). In the presence of MG132, CaspPS1C was also detected 
in NCT-/- and Pen-2-/- cells (lanes 4 and 8). However, in contrast to wt, PS2-/-, and 
Aph-1-/- cells, the increase in CaspPS1C was not associated with a decrease, but 
rather an increase in the regular PS1C in NCT-/- cells (compare lane 4 with lane 
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3) and Pen-2-/- cells (compare lane 8 with lane 7). Interestingly, as shown in the 
bottom panel, the high levels of unprocessed CTFα(endo), CTFα-myc, and CTFβ 
in NCT-/- and Pen-2-/- cells were not affected by the addition of MG132. These 
results indicate that recovery of PS1C does not necessarily restore -secretase 
activity toward CTFα and CTFβ. In other words, Pen-2 and, specifically, NCT, as 
essential components of -secretase, must play a direct role in -secretase 
activity in addition to their roles in stabilizing PS1 proteolytic products. In this 
regard, NCT has been proposed to function as a substrate receptor (Shah, Lee 
et al. 2005).  
Discussion  
 
Previous studies using reconstitution and knockdown approaches have 
suggested that the four proteins, presenilin (PS1 or PS2), NCT, Aph-1, and Pen-
2, are necessary and sufficient for -secretase activity (Edbauer, Winkler et al. 
2003, Kimberly, LaVoie et al. 2003, Takasugi, Tomita et al. 2003). However, this 
view was challenged by a recent study showing that Notch was processed in a -
secretase-dependent manner in NCT-deficient cells, suggesting that NCT is not 
absolutely required for -secretase activity (Zhao, Liu et al. 2010). In the current 
study, by taking advantage of the availability of all cell lines deficient in one of the 
four components of the -secretase complex, we performed a series of 
experiments to attempt to address this controversial issue. Using these cells, our 
results demonstrated that knockout of PS2 had almost no effect on APP CTFs 
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processing and that, in contrast, knockout of PS1 strongly inhibited APP CTF 
processing as determined by the turnover of CTFα, as well as the formation of 
AICD and Aβ40. These observations confirmed that PS1 accounts for the majority 
of -secretase activity that catalyzes the processing of APP CTFs. In addition, our 
results revealed several interesting findings. First, our data demonstrate that, in 
contrast to NCT-/- and Pen-2-/- cells, in which no significant CTFα turnover and 
only a small amount of Aβ40 was detected, similar to wt cells, a low level of CTFα 
and significant amount of AICD were detected in Aph-1-/- cells. Also, the turnover 
of CTFα and the formation of AICD were strongly inhibited by -secretase 
inhibitor, suggesting that the turnover of CTFα and the formation of AICD in Aph-
1-/- cells, as well as in wt cells, were catalyzed by -secretase. In addition, 
another -secretase substrate, Notch, was also processed in a -secretase-
dependent manner in Aph-1-/- cells. Furthermore, based on the levels of Aβ40 
determined by ELISA, it is assumed that over 50% of -secretase activity was 
retained in Aph-1-/- cells. Although it cannot be ruled out that the trace amount of 
the residual Aph-1c, which was not detectable at the protein level under our 
experimental conditions, may contribute to a small portion of the -secretase 
activity in Aph-1-/- cells, all these observations strongly suggest that Aph-1 is not 
absolutely required for -secretase activity. In addition, albeit at a very low level, 
the detection of Aβ40 by ELISA in NCT
-/- and Pen-2-/- cells suggests that deletion 
of one of these two components does not completely abolish -secretase activity. 
Thus, it is very likely that Aph-1, NCT, and Pen-2 are all required for achieving 
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maximal -secretase activity; however, Aph-1 is less crucial than NCT and Pen-2 
for the enzymatic activity in this -secretase complex.  
It is proposed that -secretase harbors both endopeptidase-like and 
carboxypeptidase-like activities, catalyzing a series of sequential cleavages of 
APP and leading to the generation of Aβ peptide. In this model, APP is first 
cleaved at the ε-cleavage site by endopeptidase-like activity to release the APP 
intracellular c-terminal domain, AICD, and generate the membrane-bound, long 
Aβ49 peptide, which is further sequentially chopped down roughly every three 
residues by carboxypeptidase-like activity to produce the secreted Aβ40 and Aβ42 
and other minor, shorter Aβ species (Xu 2009). Previous studies suggest that 
Aph-1 might function as a scaffold involved in -secretase complex assembly and 
maturation (LaVoie, Fraering et al. 2003, Luo, Wang et al. 2003) and in the 
binding of substrate (Chen, Guo et al. 2010, Mao, Cui et al. 2012). In determining 
the specific roles of different isoforms of Aph-1 in -secretase-catalyzed APP 
processing, recent studies further suggest that Aph-1 mainly affects the 
carboxypeptidase-like activity that catalyzes the sequential cleavages following 
the initial cleavage at the ε-site and determines the C-termini of Aβ species; 
specifically, -secretase complexes containing the Aph-1b isoform favor the 
generation of longer Aβ peptides (Serneels, Dejaegere et al. 2005, Serneels, Van 
Biervliet et al. 2009, Acx, Chávez-Gutiérrez et al. 2014). This notion might 
provide justification for our finding that Aph-1 is dispensable for the 
endopeptidase-like activity of -secretase that catalyzes the initial cleavage of 
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CTFs at the ε-site, which is a decisive step in -secretase-catalyzed APP 
processing (Xu 2009).  
The second important finding of the current study is the differential 
requirement for NCT in -secretase-catalyzed processing of APP and Notch. To 
elucidate the specific function of NCT, a well-designed study revealed that the 
extracellular domain of NCT is essential for recognition of the substrate of -
secretase, suggesting that NCT functions as a receptor of substrate (Shah, Lee 
et al. 2005). However, a recent study showing that cells deficient in NCT were 
capable of processing Notch and, to a lesser extent, APP in a -secretase-
dependent manner raised a question as to whether NCT is absolutely required 
for -secretase activity (Zhao, Liu et al. 2010). Using the same NCT-/- cells and 
the same truncated Notch-expressing plasmid as used in Zhao et al’s study, our 
results revealed a similar finding that Notch was processed by -secretase 
activity in the absence of NCT. In addition, our results revealed that Aph-1 was 
also not absolutely required for Notch processing. However, in contrast to the 
previous study, our data demonstrate that knockout of NCT completely abolished 
-secretase-catalyzed processing of CTFα and CTFβ produced from both 
endogenous and recombinant APP. 
These controversial observations might have resulted from the use of 
different experimental systems. Specifically, in the previous study, a transiently-
expressed truncated APP (C99), an artificial CTFβ, was used as a -secretase 
substrate to determine the effect of knockout of NCT on the formation of AICD 
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from C99. In contrast, in the current study, we examined the processing of CTFα 
and CTFβ produced either from endogenous APP or recombinant full-length 
APP. After synthesis, full-length APP undergoes multiple post-translational 
modifications including N- and O-glycosylation, phosphorylation, and tyrosine 
sulphation, and these modifications not only affect the trafficking but also the 
processing of APP along the secretory pathway as well as the endocytotic 
pathway (Jiang, Li et al. 2014). It is not known whether the overexpressed C99 
also undergoes similar post-translational modification and is processed at the 
same subcellular locations as full-length APP. Whether possible differences in 
post-translational modification and trafficking may account for the discrepancy 
between results of the current study and that reported by Zhao et al awaits 
further investigation. Nevertheless, the data presented in this study strongly 
suggest that NCT is crucially essential for -secretase-catalyzed processing of 
CTFα and CTFβ produced from full-length APP, but that NCT is not absolutely 
required for Notch processing. Supporting our finding, a recent study reported 
that mutations in NCT differentially affect Aβ production and Notch processing 
(Pamrén, Wanngren et al. 2011). Thus, this differential requirement for NCT in -
secretase-catalyzed processing of APP and Notch suggests NCT as a 
therapeutic target for developing a strategy to restrict Aβ formation in AD without 
impairing Notch signaling.  
The third notable finding of the current study is that components of the -
secretase complex essential for -secretase-catalyzed APP processing are also 
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important for proteasome- and lysosome-dependent degradation of APP 
derivatives. Previous studies have reported that, in addition to -secretase-
catalyzed processing, APP and CTFs of APP are also subjected to proteasome 
and lysosome degradation (Skovronsky, Pijak et al. 2000, Nunan, Shearman et 
al. 2001, Vingtdeux, Hamdane et al. 2007, Watanabe, Hikichi et al. 2012, Wang, 
Sang et al. 2015). In the current study, as shown in Figure 1. 1 and  1. 2, our 
data demonstrate that proteasome inhibitor MG132 and, specifically, lysosome 
inhibitors chloroquine, leupeptin, and NH4Cl caused marked accumulation of 
unprocessed APP CTFs in wild-type cells. A similar effect of these inhibitors on 
the accumulation of APP CTFs was also observed in PS1-/-, PS2-/-, and Aph-1-/- 
cells, which all expressed the -secretase activity that catalyzes the processing of 
APP CTFs. However, the effects of these inhibitors on the accumulation of the 
APP CTFs was less significant in PS1/2-/-, NCT-/-, and Pen-2-/- cells, in which no 
-secretase-catalyzed APP processing was observed. These findings strongly 
indicate that presenilin (PS1 or PS2), NCT, and Pen-2, which are essential for -
secretase-catalyzed APP processing, are also important for proteasome- and 
lysosome-dependent degradation of APP CTFs. One possibility is that -
secretase activity is involved in the proteasome- and lysosome-dependent 
degradation of APP CTFs. However, this is very unlikely in light of the fact that -
secretase inhibitors and the proteasome and lysosome inhibitors exhibited 
additive effects on the accumulation of APP CTFs. Recent studies reported that 
presenilin is necessary for efficient protein degradation by lysosome in a -
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secretase-independent manner (Lee, Yu et al. 2010, Neely, Green et al. 2011, 
Coen, Flannagan et al. 2012, Zhang, Garbett et al. 2012). In this regard, it is 
noteworthy that our results suggest that lysosome plays a major role in 
degradation of APP CTFs. Therefore, the inefficient degradation of APP CTFs in 
PS1/2-/- cells is likely due to impaired lysosome function caused by deficiency of 
presenilin. Since NCT and Pen-2 are essential for stabilizing presenilin (Mao, Cui 
et al. 2012), the ineffective lysosomal degradation of APP CTFs in NCT-/- and 
Pen-2-/- cells might have resulted from the instability of presenilin in these cells. It 
is also noted that the level of PS1C in Aph-1-/- cells is much higher than that in 
NCT-/- and Pen-2-/- cells, and this might account for the fact that lysosomal 
degradation of APP CTFs was observed in Aph-1-/- cells. However, it cannot be 
ruled out that NCT and Pen-2 may be directly involved in PS1-regulated 
lysosome function rather than simply stabilizing PS1C. In addition, our results 
strongly suggest that endogenous and exogenous APPs undergo degradation by 
different mechanisms, i.e., endogenous APP mainly undergoes lysosome-
dependent degradation, whereas, exogenously expressed APP is primarily 
degraded by proteasome.  
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Figure 1. 1 Aph-1 is dispensable for γ-secretase catalyzed APP processing. 
Cells were cultured in the presence and absence of γ-secretase inhibitor L-
685,458 (a) or MG132 (b) overnight, lysed, and subjected to 16% SDS-PAGE 
and Western blot analysis using antibody C15 that was raised against the very c-
terminal 15 residues of APP. The membranes were also reprobed with anti-
GAPDH to indicate even loading of the samples (bottom panels). All data 
presented in this study are representative of at least three independent 
experiments. (c) Cell-free assay for in vitro generation of AICD. AICDendo: AICD 
produced from endogenous APP; AICDmyc: AICD produced from myc-tagged 
exogenous APPSw in a wt-7 stable cell line, which was used as a positive 
control. (d) Effect of knockout of different components of γ-secretase on Aβ 
formation. Aliquots of CM samples of knockout cells were subjected to ELISA to 
detect Aβ40. A significant amount of Aβ40 was detected in Aph-1
-/- cells, as well as 
in wt cells. Low amount Aβ40 was also detected in PS1
-/- cells, and even lower 
Aβ40 was detected in NCT
-/- and Pen-2-/- cells. N = 3, *p < 0.01; **p < 0.001. (e) 
Western blot analysis of protein levels of γ-secretase components in knockout 
cells. (f) RT-PCR analysis of NCT and Aph-1 genes in corresponding knockout 
cells. Note: Since Aph-1c is the duplicate of Aph-1b in mice, the antibody against 
Aph-1b also detects Aph-1c, and the RT-PCR primers used are also common to 
both Aph-1b and Aph-1c. 
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Figure 1.1 continued 
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Figure 1.2 Components of the γ-secretase complex also play a role in regulating 
APP degradation by proteasome and lysosome. (a) Effects of γ-secretase, 
proteasome, and lysosome inhibitors on the accumulation of unprocessed 
endogenous CTFα. The first lane is the vehicle-treated control. The last lane is 
the sample prepared from wt-7 cells treated with γ-secretase inhibitor compound 
E (compE) used as standards of CTFβ-myc and CTFα-myc. (b) In lanes 3–10, 
cells were transfected with human APPsw expression plasmid. In lane 2, cells 
were transfected with unrelated protein LacZ. In lane 1, cells were mock 
transfected with an empty vector. Lane 11 is the sample prepared from wt-7 cells 
treated with compound E used as standards of CTFβ-myc and CTFα-myc. All 
APP CTFs were detected using C15. (c) Quantitative analysis of the formation 
and turnover of APP-CTFs. Results are expressed as the mean (± SD) of three 
independent Western blot results shown in Figure 1. 2b. 
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Figure 1.3 γ-secretase, proteasome, and lysosome inhibitors have an additive 
effect on CTFα accumulation in Aph-1-/- cells. (a) Cells in lanes 2–10 were 
cultured in the presence of γ-secretase inhibitors and proteasome and caspase 
inhibitors either individually or in combination. Top panel, immunoblot probed 
with C15; second panel, immunoblot probed with anti-caspase-3 to detect the 
formation of the active form of caspase-3; third panel, immunoblot probed with 
anti-caspase-6 to determine the reduction of pro-caspase-6 due to activation; 
fourth panel, immunoblot probed with anti-PS1C, which reacts with both regular 
PS1C and the caspase-produced CaspPS1C (#5643 from Cell Signaling); the 
immunoblot in the fourth panel was also reprobed with anti-GAPDH to indicate 
relative loading of samples (bottom panel). Lane 11 is the sample from wt-7 cells 
cultured in the presence of compound E. (b) Cells in lanes 2–10 were cultured in 
the presence of γ-secretase inhibitors and lysosome inhibitors either individually 
or in combination. Top panel, immunoblot probed with C15; bottom panel, this 
immunoblot was reprobed with anti-GAPDH. Lane 11 is the sample from wt-7 
cells cultured in the presence of compound E. 
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Figure 1. 3 a 
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Figure 1.3 continued 
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Figure 1. 4 a 
 
 
 
 
 
 
 
 
 
Figure 1. 4 b 
Figure 1.4 Aph-1 and nicastrin are not essential for γ-secretase catalyzed 
processing of Notch. (a) Aph-1-/- cells were transfected with a plasmid expressing 
N-terminal truncated Notch with a C-terminal myc tag. Top panel, immunoblot 
probed with anti-myc to detect the unprocessed recombinant Notch. Middle 
panel, immunoblot probed with antibody, which specifically recognizes the N-
terminus of NICD generated by γ-secretase processing. Bottom panel, 
immunoblot in the middle panel reprobed with anti-GAPDH. (b) Proteasome and 
lysosome have no significant effect on Notch metabolism. Top panel, immunoblot 
probed with anti-myc to determine the levels of NotchΔE in the presence of 
different inhibitors; middle panel, immunoblot probed with anti-NICD; bottom 
panel, immunoblot in middle panel was reprobed with anti-GAPDH. 
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Figure 1. 5 
 
Figure 1.5 Recovery of PS1C does not necessarily restore the γ-secretase 
activity toward APP in NCT-/- cells. Knockout cells were cultured in the presence 
or absence of MG132. Up panel, immunoblot probed with anti-PS1C that 
recognizes both regular and caspase produced PS1C; bottom panel, immunoblot 
probed with C15. Lane 12 is the sample prepared from wt-7 cells treated with 
compound E used as standards of CTFβ-myc and CTFα-myc. 
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Abstract 
 
In the previous chapter, we investigated the γ-secretase activity in various knock 
out cells. In this chapter, we found that the apoptosis in these knockout cells 
varied too. Aph-1-/- cells show a higher susceptibility to apoptosis, induced by 
MG132 via downregulation of Akt-mediated anti-apoptotic pathway. We also 
found several forms of PS1C, but the function of them remain unclear. In this 
chapter, we also used different methods to investigate the function of these forms 
in -secretase activity. The results of transfecting varied forms of PS1C back to 
PS1/2-/- double knockout cells shown that all the PS1C forms could process 
Notch when transfecting together with PS1N. However, only the shorter form of 
PS1C299 shown significant effects on restoring secretase activity toward APP 
processing. The phosphorylation of PS1C does not show significant effect on 
secretase catalyzed CTF processing under our experimental conditions.  
 
Introduction 
 
MG132, which is known as a proteasome inhibitor, could also induce apoptosis 
and autophagy at higher concentration through the upregulation of ER stress in 
various cells (Park, Jun do et al. 2011, Bao, Gu et al. 2016). Treatments of MAP 
kinase (JNK, p-38, MEK and so on) inhibitors were reported to be able to reduce 
apoptosis induced by MG132 (You and Park 2011), suggesting that these 
kinases contribute to MG132-induced apoptosis. Numbers of transcriptional 
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factors like NF-B, p53 and stat3 were reported to be involved in the autophagy 
induced by proteasome inhibitors (Saji, Higashi et al. 2011, Pietrocola, Izzo et al. 
2013). The addition of MG132 could induce the activation of a series of apoptosis 
related protein: like caspase 3, 7, 9, Bak, PARP and so on (Park, Jun do et al. 
2011). Unlike kinases mentioned above, which promote apoptosis upon 
activation, the activation of Akt was shown to suppress apoptosis (Qin, Wang et 
al. 2010, Kahana, Finniss et al. 2011). Like ERK and PKC, Akt is regarded as a 
suppressive kinase in cell death induction (Scanga, Ruel et al. 2000, Franke, 
Hornik et al. 2003). Activated Akt (p-Akt) can phosphorylate and inactivate GSK3 
(Ruvolo, Qiu et al. 2015). Therefore, the level of phosphorylated GSK3 could be 
used as an indicator for the activation of Akt.  
    In this study, we found that the same concentration of MG132 could induce 
varied level of apoptosis in different knock out cells. Among these cells, Aph-1-/- 
cells have a higher tendency of apoptosis based on the levels of PARP cleavage 
and activation of caspase 3 and caspase 7. The phosphorylation levels of 
kinases which mediate apoptosis, like JNK, p-38, c-Jun (Ferraris, Isoniemi et al. 
2012) and transcriptional factor CHOP (Teske, Fusakio et al. 2013) were found 
increased in Aph-1-/- , NCT-/-, Pen-2-/-, PS1-/-, PS2-/- and WT cells. But unlike the 
other knock out cells, the level of the active form of the apoptosis suppressive 
kinase p-Akt is reduced in Aph-1-/- cells. The downregulation of p-Akt in the 
absence of Aph-1 might account for the higher tendency of apoptosis in Aph-1-/- 
cells. Based on the previous results, p-GSK3 located downstream of p-Akt is 
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phosphorylated by p-Akt. Therefore, the reduction of p-GSK3 is consistent with 
the reduction of p-Akt and further confirmed that the downregulation of p-Akt in 
the absence of Aph-1 upon treatment with MG132.  
    PS1 was first reported of going through endoproteolysis at 1996 and the 
cleavage sites range from 260aa to 320aa (Thinakaran 1996). Later report 
identified the more specific processing sites located on aa292. Since the 
mutation at aa 292 could almost abolish the endoproteolysis of PS1 (Steiner, 
Romig et al. 1999). Further investigation revealed that like -secretase substrate 
APP, the endoproteolyis of PS1 also follows a three-amino acid spacing manner 
and occurs sequentially at multiple sites at aa 293, aa 296 and aa 299 (Xu 2009, 
Fukumori, Fluhrer et al. 2010).  
    An apoptotic fragment of PS1 and PS2 were first reported of cleavage results 
by caspase 3. And the cleavage sites in PS1 was reported within 343aa to 346aa 
(Kim 1997). Two years later, besides the above one, another cleavage site was 
detected at 329 aa which is processed by the group of caspase 8, 6 and 11 
(Craen 1999). In addition to the normal PS1C and caspase cleaved PS1Cs, 
phosphorylated PS1Cs were also reported. For example, the one phosphorylated 
by GSK3 at Ser353, Ser357 or Ser397, Ser401 (Kirschenbaum, Hsu et al. 2001, 
Twomey and McCarthy 2006), the one phosphorylated by cyclin-dependent 
kinase 5/p35 (cdk5/p35) on Thr354(Lau, Howlett et al. 2002), a PKC 
phosphorylated one on Ser346(Fluhrer, Friedlein et al. 2004) and so on. A recent 
paper have check almost all the phosphorylated PS1 and conclude that these 
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phosphorylation of PS1 do not modulate the activity of -secretase and therefore 
should not be considered as targets of AD treatment (Matz, Halamoda-Kenzaoui 
et al. 2015).  
    Based on our previous results and the papers mentioned about all the PS1 
fragments above, including PS1N (1-292aa), PS1C (PS1C293, PS1C296, PS1C299, 
PS1C334, PS1C346 and phosphorylated PS1), we suspect that they might have 
different effects on γ-secretase activities. Therefore, we designed several 
experiments to determine their function. First, we used phosphatase to remove 
the phosphorylation of PS1C and check the activity of PS1C at process CTFs 
and found that the phosphorylation of PS1C does not contribute to gamma 
secretase activity. Then we also constructed different forms of PS1Cs, the 
PS1C293, PS1C296, PS1C299, PS1C334 and PS1C346 and a PS1N (1-292aa). We 
transfected these PS1Cs in combination with PS1N back to PS1/2-/- cell together 
with NotchΔE or APPsw. We found that the transfection with PS1C (no matter 
which form) alone or PS1N alone could not process NotchΔE or APP. While, 
when both PS1N and PS1C (no matter which PS1C form) were transfected into 
cells together, processing of NotchΔE was readily detectable. However, the 
ability of these PS1Cs to process APP was different. Our results demonstrated 
that the PS1C299 is the most effective form in processing APP in comparison with 
other PS1C of different length. This result suggests that PS1C299 might contribute 
more to APP processing.  
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Materials and Methods 
Cell culture   
MEF cells we used in this part were the same from the last chapter: including 
Aph-1-/- , NCT-/-, Pen-2-/-, PS1-/-, PS2-/-, PS1/2-/-, wild type (wt) and wt-7 cells.  All 
cells were cultured in Dulbecco’s modified Eagle’s  medium (DMEM, Lonza, 
Walkersville, MA, USA) which containing 10% fetal bovine serum, 2 mM L-
glutamine (Lonza), 100 units/mL penicillin (Lonza), and 100 μg/mL streptomycin 
(Lonza).  
Inhibitors and reagents 
We used proteasome inhibitor MG132 and gamma-secretase inhibitor 
Compound E in this chapter and like which mentioned in last chapter: MG132 
was purchased from Peptides International (Louisville, KY, USA), Compound E 
and DAPM were purchased from EMD Millipore (Billerica, MA, USA). Complete 
protease inhibitor cocktail tablets were purchased from Roche Applied Science 
(Indianapolis, IN, USA). Lipofectamine LTX and plus reagent was purchased 
from Invitrogen (Carlsbad, CA, USA). Phosphatase was purchased form Sigma-
Aldrich (St. Louis, MO, USA).  
Antibodies 
Antibodies which were anti-PS1C5643, PS1C3622, c-Notch (#4147, which 
specifically recognizes the processed Notch), PARP, caspase3, caspase-7, p-
cJun, p-JNK, JNK,  p-p38, p38, CHOP(C/EBP-homologous protein), p-Akt, Akt, 
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and p-GSK3 (Ser-9) were purchased from Cell Signaling (Danvers, MA). 
Polycolonal antibody C15 was raised against the last 15 amino acids at the very 
C terminal of APP (Zhao, Mao et al. 2004). Polycolonal antibody 6E10 was 
purchased from Covance (Princeton, NJ, USA). Anti-myc antibody, C-Myc 
(9E10), was purchased from Santa Cruz (Dallas, TX, USA). Anti-GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase) was from EMD Millipore (Billerica, 
MA).  
Plasmids 
We used NotchΔE and APPsw plasmid which as mentioned in last chapter: 
plasmid expressing the extracellular region truncated and myc-tagged Notch 
molecule (NotchΔE) containing the murine Notch-1 leader peptide (1-23 aa) 
(Kopan, Schroeter et al. 1996) was kindly provided by Raphael Kopan 
(Washington University) and Dr. Masayasu Okochi (Osaka University, Japan). 
The plasmid APPsw, which expresses a C-terminal myc-tagged Swedish mutant 
APP (APPsw) (Thinakaran, Teplow et al. 1996), was kindly provided by Dr Gopal 
Thinakaran (University of Chicago). The plasmids which expressing the PS1N 
terminal (1-292aa), PS1C terminals: PS1C293 (293-467aa), PS1C296 (296-467aa), 
PS1C299 (299-467aa), PS1C334(334-467aa), PS1C346 (346-467aa) were 
constructed in our lab and sequenced to confirm.  
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SDS-PAGE and Western blotting 
For analysis of apoptosis and autophagy related proteins, 10 h after splitting, 
cells were incubated overnight in the presence or absence of MG132 at different 
concentrations (check the legends for concentration details). For the analysis of 
the activity of gamma secretase, gamma secretase inhibitor compound E (5nM) 
was applied the same like above. For analysis of the exogenous APP and Notch 
processing through different PS1C and PS1N terminals, the cells, 24 h after 
splitting, were transfected with plasmids expressing APPsw or NotchΔE with 
lipofectamine LTX. Twelve hours after the transfection of APPsw or NotchΔE, 
PS1N and PS1C terminals were transfected and the cells were further incubated 
for about 24 hours. For the detection of the function of phosphorylated PS1C, 
cells were grown for 24 hours and then collected with dephosphorylation buffer 
(suggested by sigma) and incubated in 37℃ for 2 hours with inhibitors and 
phosphatase (check figures and figure legend for details). Cell lysis and Western 
blot analysis were carried out as described previously (Zhao, Mao et al. 2004), 
which is consistent to which described briefly in last chapter. The membranes 
were probed with appropriate antibodies as described in Figure legends.  
Results 
Presenilin 1 C terminal levels varied in different knock out cells with the 
addition of MG132. 
As a proteasome inhibitor, MG132 could block the degradation of PS1 C 
terminals from degrading through proteasome pathway. Therefore, the 
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accumulation of PS1 C supposed to be observed with the presence of MG132 in 
the knock out cells. Increased levels of PS1 C were observed in NCT knock out 
(Figure 2.1 upper panel, compare lane 4 with lane 3) and Pen-2 knock out cells 
(lane6 with lane5), even the volume differed. In PS2 knock out cells and WT cells, 
the level of regular PS1C seemed unchanged with the detection of one antibody 
(5643 from cell signaling, upper panel, compare lane 10 with lane 9, lane 12 with 
lane 11). But the levels of PS1 C were increased with the detection of another 
antibody (3622 from cell signaling, the lower panel), which is due to the fact that 
different epitopes were recognized by these two antibodies. Antibody 3622 could 
recognize the PS1 C from aa293 to aa313, based on our experiment, it could 
only recognize the longer form of PS1 C, which is from the amino acid 293 (aa) 
to aa467 (PS1C293 in short), but could not recognize the other forms, like the 
peptide start from aa 296 to aa467 (PS1C296 in short), aa299 to aa467 (299 in 
short) or the even shorter forms which are processed by caspases (picture2.1, 
upper panel). Based on the results detected by antibody 3622, the level of longer 
form: PS1C293 was marginally expressed in different knock out cells and WT cell 
(lane1, 3, 5, 9 and 11, figure2.1 lower panel). The majority of PS1C was either 
processed into short form: PS1C296 and PS1C299 or go through random 
degradation through proteasome pathway. As shown in figure 2.1, with the 
addition of proteasome inhibitor MG132, PS1 C’s level was dramatically 
increased when detected with 3622 in all knock out cells besides Aph-1 knock 
out cells and WT cells. When combined with the results detected by 5643 
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antibody which could detect all the PS1 C terminals, including the PS1C293, 
PS1C296, PS1C299 and the caspase cleaved PS1Cs, we can see the level of total 
PS1 C was much lower in Aph-1 knock out cells, especially when comparing with 
NCT knock out cells (compare lane 2 with lane 4, figure2.1 upper panel). On the 
other hand, the caspase cleaved PS1 C was much higher in Aph-1 knock cells 
(compare lane 2 with lane 4, picture2.1 upper panel). Therefore, we speculate 
that the majority of PS1C were processed through caspase activity in Aph-1 
knock out cells. Cells have higher apoptosis rate when induced by MG132 in 
Aph-1 knock out cells.  
    Subsequently, we conducted the following experiments to check the caspase 
activity in all knock out cells and WT cells with the presence of MG132.  
Cells have a higher tendency of apoptosis with MG132 addition in the 
absence of Aph-1. 
Based on the results in Figure 2.2, comparing lane 2 with lane 4, 6, 8, 10 and 12, 
the level of active form of caspase 3, caspase 7 and the cleavage of PARP were 
much higher in Aph-1 knock out cells than which induced in NCT knock out cells, 
Pen-2 knock out cells, PS1 knock out cells, PS2 knock out cells and WT cells by 
MG132.  Therefore, we can conclude that the some concentration of MG132 
addition trigger more apoptosis in the absence of Aph-1. We also noticed that 
knock out of NCT and PS2 could also result in a higher tendency of apoptosis but 
was much less compared to which caused by the deletion of Aph-1. 
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Apoptosis suppressive protein is down regulated in Aph-1 knock out cells. 
Since MG132 is a proteasome inhibitor and an autophagy inducer and thus could 
induce apoptosis through the upregulation of ER stress with the accumulation of 
redundant proteins. Since the previous experiment has already demonstrated 
that caspase activity is much stronger in the absence of Aph-1, we examined the 
kinases involved in apoptosis. Based on the results in Figure 2.3, pro-apoptotic 
kinases p-c Jun, p-JNK, p-p38 were upregulated in a similar level in all the cells. 
However, the level of p-Akt (anti-apoptotic kinase) was highly differed in different 
cells with the addition of MG132. Compare lane 3 with lane 4, lane 5 with lane 6, 
MG132 induced higher expression of p-Akt in NCT knock out cells and Pen-2 
knock out cells which could result in reduction of apoptosis. For PS1 knock out 
cells and WT cells, the level of p-Akt remained similar even with the addition of 
MG132. However, in PS2 knock out cells the p-Akt level was a litter bit lower. 
The dramatic reduction of p-Akt was found in Aph-1 knock out cell. The 
significant reduction of apoptosis suppressive protein: p-Akt, in Aph-1 knock out 
cells could be a reasonable cause that could explain the higher induction of 
apoptosis in Aph-1 knock out cells. The p-GSK3 which is phosphorylated through 
p-Akt followed the same pattern of p-Akt (Figure 2.3 the panel detected with p-
GSK3). The reduction of p-GSK3 level was much obvious in Aph-1 knock out 
cells than the other cells (compare lane 2 with lane1, lane 4 with lane 3, lane 6 
with lane 5, lane 8 with lane7, lane 10 with lane 9 and lane 12 with lane11).  
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The difference of apoptosis induced with MG132 become significant at the 
concentration of 5uM. 
The concentration of MG132 we used in previous experiments is 5uM since it is a 
recommended concentration as a proteasome inhibitor. But how it affects 
apoptosis and the activation of Akt are not known, so different concentration of 
MG132 were tested in Aph-1 knock out cell, NCT knock out cell and WT cell. The 
reason we choose Aph-1 knock out cell and NCT knock out cell is that the 
difference of PS1C detected in these two cells were most dramatic, which 
indicate that the apoptosis in these two cells differ most from each other. Based 
on the results of Figure  2.4, we found that the induction of caspase activity and 
apoptosis induced kinase like p-c Jun, p-p 38, p-JNK follow a dose dependent 
manner. We also found the increase of caspase activity in Aph-1 knock out cells 
was faster which further support the idea that the absence of Aph-1 lead to 
higher preference of apoptosis. The reduction of p-Akt and p-GSK 3 also 
followed a dose dependent manner in Aph-1 knock cells and became very 
significant at the concentration of 5uM which was used in the previous 
experiments. We have also checked the effect of the addition of higher 
concentration of MG132. The results demonstrated that 5uM is suitable to show 
the difference since the increased level of MG132 (10uM) did not cause more 
reduction of p-Akt and p-GSK3 in Aph-1 knock out cells (Figure 2.5, compare 
lane 4 with lane 3). Therefore, in this project, 5uM is a suitable concentration for 
both proteasome degradation protection and apoptosis induction.  
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The only transfection of PS1C terminal fragments or PS1N fragments could 
not process NotchΔE. 
To illustrate the potential functions of truncated PS1C terminals and N terminals 
at restoring gamma secretase activity, we constructed varied PS1 C terminals 
with the length from amino acid 293, 296, 299, 334, 346 to the very end of C 
terminal (name as PS1C293, PS1C296, PS1C299, PS1C334 and PS1C346) and PS1 
N terminal starting from amino acid 1 to 292 (short as PS1N).  As shown in the 
upper panel of Figure 2.6, with the detection of antibody 5643, PS1wt, PS1C293, 
PS1C296, PS1C299, PS1C334 and PS1C346 and PS1N were successfully 
transfected into the PS1/2 double knock out cells. The results shown by antibody 
3622 confirmed that the band detected with 3622 was the longer form of PS1C 
which was PS1C293 (lane 5), since the other forms of PS1 C could not be 
detected by antibody 3622 (compare lane 5 with lane 6, 7, 8 and 9). The third 
panel was probed with -myc antibody which shown similar transfection level of 
NotchΔE in the cells transfected with varied PS1C terminals PS1N terminal. 
Even with the equal transfection of NotchΔE, the processing of it differed 
dramatically due to the transfection of varied PS1C and PS1N. In the panel 
detected with c-Notch which could only recognize the processed C terminal of 
NotchΔE, we found NotchΔE was only processed with the transfection of PS1wt 
rather than any other PS1 C terminals or PS1 N terminal (compare lane 4 with 
lane 5, 6, 7, 8, 9 and 10). This result demonstrated that the only transfection of 
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PS1C or PS1N could not restore the activity of gamma secretase at processing 
NotchΔE.  
NotchΔE could be processed by the double transfection of PS1C terminal 
fragments (all the truncated PS1 Cs) and PS1N fragments.  
Since the single transfection of PS1C or PS1N could not process NotchΔE, we 
suspect the processing of NotchΔE might require the integrity of PS1. So we 
transfect different PS1C terminals separately but together with PS1N terminals, 
results (Figure 2.7) shown that the transfection of PS1 Cs and PS1N were 
successful (upper two panels). The NotchΔE expression in all the transfected 
cells were equal (the third panel detected with -myc antibody). The results 
shown by c-Notch immunoblot was interesting, all the PS1C transfected with 
PS1N terminals could process NotchΔE and the c-Notch levels were similar to 
which processed by PS1 wt plasmid (compare lane 5, 6, 7, 8 and 9 with lane 4 in 
panel 4). This result demonstrated that the PS1Cs transfection together with 
PS1N could restore the activity of -secretase at processing NotchΔE, and the 
restoration is not obviously affected by the length of PS1 C. No matter how the 
PS1C starts from 293, 296, 299, 334 or 346, they all could process NotchΔE with 
PS1N.  
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APP produced CTF could be processed by the double transfection of 
PS1C terminal fragments (all the truncated PS1 Cs) and PS1N fragments 
differently.  
Another important substrate of gamma secretase is CTFs. Our results above 
have already demonstrated the processing of NotchΔE does not differ with the 
transfection of varied length of PS1 C. The next thing is to determine the pattern 
of the processing of CTFs by varied PS1C terminals. Since our CTFs and PS1 
levels in all the knock out cells suggest that the length of PS1 C might contribute 
to the ability of gamma secretase at the processing of CTFs. The upper two 
panels in Figure 2.8 demonstrated the success of the transfection of PS1 C and 
PS1 N terminals in PS1/2 double knock cells. The third panels shown the 
transfection of APP in all the lanes were similar. But immunoblot with C15 
indicated that the levels of CTFs are different. There were three bands; the upper 
one was exogenous CTFbut the level was so low to show clear difference; the 
middle one was exogenous CTF. Without the transfection of APP, these two 
exogenous bands could not be detected, as shown in lane 1, the only detected 
band is endogenous CTFWe found that the transfection of PS1wt significantly 
reduced the level of CTFs (all the three bands were reduced, compare lane 4 
with lane 2 and 3). The interesting thing was the transfection of PS1C299 together 
with PS1N seemed processed more CTFs than the other PS1C fragments. It is 
suggesting that the short form of PS1 C (PS1C299) has higher activity at 
processing CTFs.   
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Phosphorylated PS1C could not process CTF. 
In the first panel of figure 2.9, the upper band is a phosphorylated PS1C, which 
could be dephosphorylated by phosphatase (compare lane 2 with the other 
lanes). First, in the absence of DAPM, even though PS1C was dephosphorylated 
(compare lane 1 with lane 2 in the first panel), CTFwas not protected or 
processed more (shown in the second panel) which suggest that the 
phosphorylated PS1C was not active at processing CTF. However, another 
possibility was that in the condition of dephophorylated buffer -secretase was 
not active at all. Therefore, as a -secretase inhibitor, DAPM (3,5-
DIFLUOROPHENYLACETYL-ALA-PHG-OME) was added to test its activity. 
Since DAPM might be removed during sample collection by multiple wash, it was 
added during wash period too. Compare lane 3 and lane 2 in the second panel, 
the processing of CTF was blocked, which confirmed that during the 2 hours 
incubation period of samples in dephosphorylation buffer with phosphatase at 
37℃, the activity of -secretase was not disturbed. Putting all together, the 
dephosphorylation of PS1C did not block or promote the processing of 
CTFthrough -secretase.  
Discussion 
 
Neuron loss is a major problem in AD. Therefore, apoptosis become a big issue 
in the searching AD treatment and therapy. It has been reported that mutant PS1 
and overexpression of PS1 could induce apoptosis (Weihl, Ghadge et al. 1999, 
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Zeng, Hu et al. 2015). And one report mentioned that the overexpression of Aph-
1a, b and pen-2 could induce an anti-apoptotic result through downregulating p-
53 controlled activity of caspase 3 and the knock out of these components will 
result in the reverse response which is increase of caspase activity and 
apoptosis with the induction of staurosporine (STS). They conclude that the anti-
apoptotic response is independent of -secretase activity but require the integrity 
of it (Dunys, Kawarai et al. 2007). Their theory and results are very supportive to 
our research here. The difference is that the apoptotic inducer we used is 
proteasome inhibitor MG132. We have found in previous study that the knock out 
of different components of -secretase result in varied viability of induction by 
MG132 (Hu, Zeng et al. 2015). But the exact roles of the -secretase component 
in apoptosis induced by MG132 and the pathways involved in MEF cells remain 
unclear. Therefore, we designed this study and found that in consistent to Dr. 
Dunys’s study, indicating the knock out of Aph-1 lowering the resistance of MEF 
cells to apoptosis. But the knock out of Pen-2 does not increase the level of 
apoptotic related activities, such as the active form of caspase 3, 7, PARP and so 
on, which is probably because we use different inducers and the pathways 
involved are totally different.  
    For instance, in our case, the activation of p53 is not affected by MG132 (not 
shown). However, the level of apoptosis suppression kinase p-Akt is dramatically 
reduced in the Aph-1 knock out cells. And the kinase GSK3 which is 
phosphorylated by p-Akt decreased correspondently, further supporting the idea 
 78 
 
that the increased apoptosis with the absence of Aph-1 is due to the lowering to 
p-Akt with the induction of MG132 in MEF cells(Scanga, Ruel et al. 2000, Franke, 
Hornik et al. 2003, Ruvolo, Qiu et al. 2015).  
    It still remains unknown how Aph-1 regulate p-Akt. The proper hypothesis 
could be p-Akt is a substrate of Aph-1 or the kinase that phosphorylated p-Akt is 
regulated by Aph-1 somehow. These directions need to be further pursued. Hope 
we will come to a more specific conclusion in the future.  
The other part of this study is to compare the activity of PS1C fragments in -
secretase through the processing of Notch and CTFs. The PS1N and PS1C 
fragments containing plasmids were constructed based on previous reports(Kim 
1997, Craen 1999) (Steiner, Romig et al. 1999) (Fukumori, Fluhrer et al. 2010). 
The phorsphorylated PS1 were reported of no -secretase activity which is 
consistent with our results (Matz, Halamoda-Kenzaoui et al. 2015). The 
dephosphorylation of PS1C does not reduce the activity of -secretase.          
    For the processing of Notch by other PS1C fragments, we found that both 
PS1N and PS1C are required. It is probably due to the necessary of the intact of 
two aspartic site: D257 and D385 which are located on PS1N and PS1C 
separately (Capell, Steiner et al. 2000). Since the PS1C fragments we created in 
this study all include aa385 and PS1N include aa257. This hypothesis is 
supported by a previous report (Kim, Ki et al. 2005) and require further 
investigation.  
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    However, the activity of PS1C (PS1C293, PS1C296, PS1C299, PS1C334, PS1C346) 
fragment at processing Notch with the accompany of PS1N do not varied 
dramatically, Only PS1C293 shown less activity when comparing to the others. 
However, at processing CTFs, the activity of PS1Cs varied obviously. The 
PS1C299  has stronger strength than the others. Since it has been reported that 
the endoproteolysis and production of PS1C is also stepwise and the final 
produced PS1C is PS1C299 in cells, we may conclude that the shedding of the 
first several amino acid is required for the processing of CTFs (Fukumori, Fluhrer 
et al. 2010). Apparently, in our study, the caspase produced PS1C fragments 
PS1C334 and PS1C346  do not have activity at processing CTFs. Based on above 
results, the processing of Notch and CTFs require different length of PS1C. The 
processing of CTFs is more complicated and need further investigation.  
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Figure 2.1 
 
Figure 2.1 Presenilin 1 C terminal levels varied in different knock out cells with 
the addition of MG132. Knockout cells were cultured in the presence or absence 
of MG132. Up panel, immunoblot probed with anti PS1C 5643 antibody that 
recognizes both regular and caspase produced PS1C; bottom panel, immunoblot 
probed with with anti PS1C 3622 that recognizes only longer form of PS1C starts 
from amino acid 293.  
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Figure 2.2 
Figure 2.2 Cells have a higher tendency of apoptosis with MG132 addition in the 
absence of Aph1.Knockout cells were cultured in the presence or absence of 
MG132. Up panel, immunoblot probed with anti  PARP; middle panel, 
immunoblot probed with caspase 3 which could recognize the full length and 
active form of caspase 3; bottom panel, immunoblot probed with caspase 7 
which could recognize the full length and active form of caspase 7. 
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Figure 2.3 
 
Figure 2.3 Apoptosis suppressive protein is down regulated in Aph1 knock out 
cells.Knockout cells were cultured in the presence or absence of MG132. And 
immunoblot probed with anti p-c Jun, p-JNK, JNK, p-p38, p38, CHOP, p-Akt, Akt, 
p-GSK3 separately. Then re-probe the p-p38 probed membrane with GAPDH for 
loading control.  
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                                                 Figure 2.4 
Figure 2.4 The difference of apoptosis induced with MG132 become significant 
at the concentration of 5uM. Knockout cells were cultured in the presence or 
absence of MG132. And immunoblot probed with anti PARP, caspase 3, caspase 
7, PS1 C 5643, PS1C 3622, p-c Jun, p-p38, p38, p-JNK, JNK, CHOP, p-Akt, Akt, 
p-GSK3 separately. Then re-probe the p-p38 probed membrane with GAPDH for 
loading control.  
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Figure 2.5 
 
Figure 2.5 The difference of apoptosis induced with MG132 become significant 
at the concentration of 5uM. Knockout cells were cultured in the presence or 
absence of MG132. And immunoblot probed with anti PARP, CHOP, p-Akt, Akt, 
p-GSK3 separately. Then re-probe the CHOP probed membrane with GAPDH for 
loading control.  
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Figure 2.6 
 
Figure 2.6 The only transfection of PS1C terminal fragments or PS1N fragments 
could not process NotchΔE. PS1/2 double knockout cells were transfected with 
different PS1 C terminals or PS1N terminals together with NotchΔE. And 
immunoblot probed with anti PS1C5643, PS1C3622, -myc, c-Notch and 
GAPDH separately.  
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Figure 2.7 
 
Figure 2.7 NotchΔE could be processed by the double transfection of PS1C 
terminal fragments (all the truncated PS1 Cs) and PS1N fragments. PS1/2 
double knockout cells were transfected with different PS1 C terminals and PS1N 
terminals together with NotchΔE. And immunoblot probed with anti PS1C5643, 
PS1C3622, -myc, c-Notch and GAPDH separately.  
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Figure 2.8 
 
Figure 2.8 APP produced CTF could be processed by the double transfection 
of PS1C terminal fragments (all the truncated PS1 Cs) and PS1N fragments 
differently. PS1/2 double knockout cells were transfected with different PS1 C 
terminals and PS1N terminals together with APP. And immunoblot probed with 
anti PS1C5643, PS1C3622, 6E10, C15 and GAPDH separately. 
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                  Figure 2.9 
 
Figure 2.9 Phosphorylated PS1C could not process CTF. WT cells were 
treated in the presence or absence of DAPM (100nM). Phosphatase was added 
in lane 2. And immunoblot probed with anti PS1C5643, C15 and GAPDH 
separately 
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CHAPTER III 
 
PEN-2 IS REQUIRED FOR NOTCH PROCESSING 
AS A SUBSTRATE RECEPTOR   
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Abstract 
Pen-2 is necessary for PS1 endoproteolysis and the stability of the heterodimer 
of PS1N and PS1C. Therefore, we suspect that the inability of processing Notch 
in Pen-2-/- cell is due to the instability of PS1. In order to test this possibility, 
PS1N and PS1C299 alone with Notch were transfected into Pen-2
-/- cell. However, 
despite the presence of significant amount of PS1N and PS1C, no  secretase 
activity was detected in these Pen-2-/- cells. This result suggests that Pen-2 is 
functionally required for -secretase activity. Furthermore, Pen-2 and PS are the 
two minimal components required for Notch processing since the knockdown of 
NCT in Aph-1 knock out cell did not affect the processing of Notch. Furthermore, 
with immunoprecipitation experiments, our results demonstrate that Pen-2 might 
functionally required for recruit substrate Notch and assist in delivering Notch to 
PS for processing. As shown in chapter II, our data have demonstrated that all 
the PS1Cs (PS1C293, PS1C296, PS1C299, PS1C334 and PS1C346) examined 
showed no difference in catalyzing Notch processing. But PS1C299 has a higher 
activity for CTFs processing. Thus, PS1C299 was chosen as a PS1C 
representative to carry out the following study. Our study supports the hypothesis 
that Pen-2 is more than a structural component of the -secretase complex and 
may contribute to the catalytic mechanism of the enzyme (Bammens, Chávez-
Gutiérrez et al. 2011). 
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Introduction 
 
Presenilin enhancer 2 (Pen-2) is a 12kD, hairpin like membrane protein (De 
Strooper 2003). Pen-2 was found to interact closely with PS and to be required 
for -secretase activity for processing CTFand Notch (Francis, McGrath et al. 
2002). Knockdown of Pen-2 resulted in the accumulation of holoprotein PS1 and 
reduction of the endproteolytic product of PS1, PS1N and PS1C. Therefore, Pen-
2 was thought to be necessary for the endoproteolysis of PS (Takasugi, Tomita 
et al. 2003). The endoproteolysis of PS is required for the activation of PS1 
functioning as the catalytic component of -secretase (Kopan and Goate 2000).  
    Pen-2 was also reported to play a role in stabilization of PS1N and PS1C 
heterodimer following endoproteolysis of PS1 (Prokop, Shirotani et al. 2004). 
Using siRNA approach, it was shown that knockdown of pen-2 also resulted in 
impaired NCT maturation and proteasomal degradation of other -secretase 
components, suggesting that pen-2 is also important for maintaining the integrity 
of -secretase complex (steiner, winkler et al. 2002, mao, cui et al. 2012). The 
important role of Pen-2 in -secretase activity was further confirmed by a recent 
study that reported that genetic knockout of Pen-2 resulted in embryo lethality 
and embryo absorbing at embryonic day 9.5, likely due to impaired Notch 
signaling (Bammens, Chavez-Gutierrez et al. 2011).  
In 2012, our group found that Pen-2 might be dispensable for endoproteolysis 
of PS1 (Mao, Cui et al. 2012). It was found that significant level of PS1C could be 
recovered by addition of proteasome inhibitor MG132 in Pen-2 knockdown cells, 
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strongly indicating that PS1 was processed in the absence of Pen-2. This result 
suggests that Pen-2 is not absolutely required for PS1 endoproteolytic 
processing, but rather more important for the stabilization of PS1 by preventing it 
from proteasome degradation (Mao, Cui et al. 2012). This finding was further 
supported by a very recent study reporting that PS1 is processed in Pen-2 
knockout cells isolated form Pen-2 knockout mice (Holmes, Paturi et al. 2014) 
These observations raised questions about whether Pen-2 participate in 
secretase activity through the regulation the formation of PS1N and PS1C 
heterodimer or Pen-2 is directly involved in -secretase catalytic mechanism per 
se remain illusive. To elucidate the exact role of Pen-2 in secretase activity, we 
conducted several experiments in this chapter. Our data clearly demonstrate that 
Pen-2 is not required for the PS1N and PS1C heterodimer formation, bur is very 
likely required for substrate recruitment of -secretase. 
  
Materials and Methods 
Cell culture   
MEF cells we used in this part were: Aph-1-/- , Pen-2-/-, PS1/2-/-, wild type (wt) and 
wt-7 cells.  All cells were cultured in Dulbecco’s modified Eagle’s  medium 
(DMEM, Lonza, Walkersville, MA, USA) which containing 10% fetal bovine 
serum, 2 mM L-glutamine (Lonza, Walkersville, MD), 100 units/mL penicillin 
(Lonza), and 100 μg/mL streptomycin (Lonza).  
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Inhibitors and reagents 
Compound E, a secretase inhibitor was purchased from EMD Millipore 
(Billerica, MA, USA). Complete protease inhibitor cocktail tablets were purchased 
from Roche Applied Science (Indianapolis, IN). Lipofectamine LTX and plus 
reagent was purchased from Invitrogen (Carlsbad, CA).  
Antibodies 
Antibodies which were anti-PS1C5643 and c-Notch (#4147, which specifically 
recognizes the processed Notch) were purchased from Cell Signaling (Danvers, 
MA). Polycolonal NCT antibody N1660 was purchased from Sigma-Aldrich 
(St.Louis, MO). Polyclonal antibody anti-PEN-2N was from Covance (Emeryville, 
CA). Anti-myc antibody, C-Myc (9E10), was purchased from Santa Cruz (Dallas, 
TX, USA). Anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was from 
EMD Millipore (Billerica, MA). Anti-PS1N was raised against a peptide 
corresponding to residues 27–50 of human PS1 (Zhao, Cui et al. 2005). 
Plasmids 
We used NotchΔE plasmid which as mentioned in last chapter: plasmid 
expressing the extracellular region truncated and myc-tagged Notch molecule 
(NotchΔE) containing the murine Notch-1 leader peptide (1-23 aa) (Kopan, 
Schroeter et al. 1996) was kindly provided by Dr. Raphael Kopan (Washington 
University) and Dr. Masayasu Okochi (Osaka University, Japan). The plasmids 
which expressing the PS1N terminal (1-292aa), PS1C terminals: PS1C293 (293-
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467aa), PS1C296 (296-467aa), PS1C299 (299-467aa), PS1C334 (334-467aa), 
PS1C346 (346-467aa) were constructed in our lab and sequenced. PS1 mutants 
applied: PS1D257A, PS1D385A, PS1D257,385A were constructed as previously 
mentioned (Xu, Shi et al. 2002).  
siRNA treatment  
Both siRNAs and delivery reagent were purchased from Life Technologies 
(Carlsbad, CA), and treatment of cells with siRNAs was carried out according to 
the manufacturer’s instruction. 
Immunoprecipitation (IP) 
Protein A sepharose was purchased from Pharmacia Biotech (Piscataway, NJ). 
After transfection for 24 hours, cells were collected with 1% Chapso buffer 
(20mM Tris pH 8.0, 150mM NaCl, 5mM EDTA and cocktail). Chapso was 
phurchased from Amresco (Solon, OH). The collected samples were then 
immunoprecipitated with varied antibodies (check figure for details) overnight at 4 
℃ in the presence of Protein A conjugated beads. After immunoprecipitation, 
samples were washed and analyzed through western blotting.  
SDS-PAGE and Western blotting 
For the analysis of the activity of gamma secretase, gamma secretase inhibitor 
compE (5nM) was applied. For analysis of the exogenous APP and Notch 
processing through different PS1C and PS1N terminals, the cells, 24 h after 
splitting, were transfected with plasmids expressing NotchΔE with lipofectamine 
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LTX. Twelve hours after the transfection of NotchΔE, PS1N and PS1C terminals 
were transfected and the cells were further incubated for about 24 hours. Cell 
lysis and Western blot analysis were carried out as described previously (Zhao, 
Mao et al. 2004), which is consistent to which described briefly in last chapter. 
The membranes were probed with appropriate antibodies as described in figure 
legends.  
Results 
 
Two aspartyl acids on PS1 were essential for the processing of Notch  
The two conserved aspartic acid residues at positions 257 and 385 in PS1 have 
been identified as the catalytic residues in -secretase by a pioneer study (Wolfe 
1999), and the hypothesis that these residues form the active site for the -
secretase enzyme complex has been well supported (Steiner, Duff et al. 1999, 
Kimberly, Xia et al. 2000). Our results presented in the previous chapter 
demonstrated that -secretase catalyzed processing of Notch was achieved by 
transfection of PS1 and PS2 double knockout (PS1/2-/-) cells with PS1N in 
combination with PS1C of different length. It is noted that all the PS1Cs 
[PS1C293(aa293-aa467), PS1C296(aa296-aa467), PS1C299(aa299-aa467), 
PS1C334(a334-aa467), and PS1C346(aa346-aa467)] examined bear the aspartyl 
residue 385 (D385), indicating that as long as the PS1C contains the D385 
residue, regardless of difference in length, it is capable of to forming a functional 
heterodimer with PS1N (aa1 to aa292), which bears the aspartyl residue 257 
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(D257), to process Notch. To test this speculation that these two aspartyl 
residues essential for PS1 function under our experimental conditions, I 
transfected PS1 plasmid and three mutant PS1: PS1D385A, PS1D257A, and 
PS1D257A/D385A along with NotchE back into PS1/2
-/- cell. As shown in Figure 3.1, 
as detected with -myc, NotchΔE, which is expressed with a myc-tag at its C-
terminal, was found expressed equally in all the transfectants, except in cells 
transfected with NotchE alone (lane 2). However, NICD, the C-terminal 
fragment produced form NotchE by -secretase activity, was only detected in 
cells expressing PS1wt (lane 4), but not in cells expressing any of these mutant 
PS1 mutant (lanes 5-7). As shown in the third panel, significant amounts of PS1, 
either PS1wt (lane 4) or mutant PS1 (lanes 5-7), were detected with antibody 
5643, which is specific to C-terminal of PS1. Specifically, mutant PS1D385A and 
PS1D257A/D385A were expressed at relatively high levels. Thus, the presence or 
absence of NICD in cells expressing PS1wt or mutant PS1 is unlikely due to 
inefficient expression levels of these PS1 variants. This result confirmed that the 
two aspartates are indeed essential for -secretase catalyzed Notch processing.  
Pen-2 is directly required for Notch processing through -secretase.  
As shown in figure 2.7, co-expression of PS1N and PS1C fragments, containing 
these two aspartates separately, was able to process Notch in PS1/2-/- cells. 
Pen-2 has been regarded as a necessary factor for endoproteolysis of PS1 
required for maturation and activation of -secretase complex by previous studies 
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(Luo, Wang et al. 2003, Takasugi 2003). This notion raises a question as to 
whether Pen-2 is merely required for endoproteolysis and stabilization of PS1. If 
that is the case, co-expression of PS1N and PS1C together may reconstitute -
secretase activity in the absence of Pen-2. To test this possibility, I transfected 
Pen-2-/- cells with PS1wt alone with NotchE or PS1N and PS1C alone with 
NotchE. As shown in figure 3.2, all PS1Cs, except PS1C293, were expressed at 
substantial levels. Specifically, a significant amount of PS1C (lane 4) was 
detected in PS1wt-transfected cells and this result further confirmed out previous 
finding that Pen-2 is not absolutely required for PS1 endoproteolytic processing 
(Mao, Cui et al. 2012). Interestingly, despite the presence of significant amount of 
PS1C and PS1N, no Notch processing product NICD was detected in PS1wt or 
PS1N/PS1C transfected cells. This result indicates that in addition of enhancing 
PS1 endoproteolytic processing and stabilization of PS1, Pen-2 is directly 
required for the catalytic activity of  secretase.  
Knockdown of NCT in Aph-1-/- cells does not affect the Notch processing.  
Data presented in chapter 1 demonstrated that knockout of Aph-1 or NCT 
separately does not affect the processing of Notch. However, it is not known 
whether as long as either one of Aph-1 or NCT presences will be sufficient to 
support the -secretase activity or both Aph-1 and NCT are not required for -
secretase catalyzed Notch processing. To address this issue, using the siRNA 
approach, I determined the effect of knockdown of NCT in Aph-1-/- cells on the 
processing of Notch. As shown in figure 3.3, knockdown of NCT was achieved by 
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all three siRNAs used (lanes 3-5, third panel). In addition, transient expression of 
NotchE was detected at fair equal levels in all the transfected cells. Surprisingly, 
NICD was detected in all the cells (lanes 1-5). This result strongly suggests that 
both Aph-1 and NCT are dispensable for Notch processing. In another word, 
Pen-2 and PS1 are sufficient for the activity of  secretase to process Notch.  
The association of PS1N and PS1C was not disturbed by the deletion of 
Pen-2.  
It is well established that PS1 is the catalytic component (De Strooper, Saftig et 
al. 1998); however the role of Pen-2 in -secretase remains elusive. The data 
presented above strongly suggest that Pen-2 is directly involved in -secretase 
activity. This finding prompts us to further investigate the mechanism by which 
Pen-2 is involved in -secretase activity. One possibility is that Pen-2 might be 
required for enhancing and stabilizing the PS1N/PS1C heterodimer formation. To 
test this possibility. I examined the effect of knockout of Pen-2 on the formation of 
PS1N/PS1C heterodimer. To do so, I transfected Pen-2-/- cells and PS1/2-/- cells 
with both PS1N and PS1C and performed co-immunoprecipitation on these cell 
lysates. As shown in figure 3.4, we found that PS1N could pull down varied 
PS1C in PS1/2-/- (bottom panel). This result confirmed that in PS1N and PS1C 
are capable of forming dimer in the absence of Pen-2. The data presented in 
figure 3.4 also demonstrated that PS1N is not only capable of forming complex 
with PS1Cs produced by normal endoproteolytic processing, such as PS1C293, 
PS1C296, and PS1C299 (lanes 4, 5, and 6), but also capable of forming complex 
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with the PS1Cs produced by caspase activity, such as PS1C334 and PS1C346 
(lanes 7 and 8). Since overexpression of PS1wt could induce apoptosis (Zeng, 
Hu et al. 2015), thus, the apoptotic PS1C346 was detected in cells transfected 
with PS1wt (lane 3). It should be noted that, because they run at the similar 
migration rate, the regular PS1C293, PS1C296, PS1C299 could not be distinguished 
from IgG light chain. These data clearly indicate that Pen-2 is not required for the 
PS1N/PS1C heterodimer formation.  
Pen-2 is required for Notch binding to PS1. 
Presenilin is the catalytic component in -secretase complex. The 
endoproteolysis of PS and the association of PS1N and PS1C were believed to 
be the key in -secretase activity. However, the deletion of Pen-2 did not affect 
the association of PS1N and PS1C, suggesting that Pen-2 might participate in 
the -secretase activity directly rather than indirectly through regulation of the 
formation and stability of the complex of PS1N and PS1C. Thus, the other 
possibility is that Pen-2 might play an important role in recruiting Notch. In order 
to test our hypothesis, I performed the following experiments.  
First, all the cells were transfected with NotchΔE alone with either empty 
vector or plasmids expressing PS1 variants. In WT cells, certain level of Notch 
was co-immunoprecipitated with Pen-2 by anti-Pen-2 antibody (lane 10, upper 
top panel). However, PS1C antibody hardly pull down any Notch (lane 11). This 
is likely due to the activity of -secretase that processes NotchE into NICD, 
which is no longer associated with PS1. Therefore, I cultured WT cells in the 
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presence of -secretase inhibitor Compoud E, which could partially block the 
processing of Notch. Indeed, Notch was pulled down by PS1C antibody in WT 
cells in the presence of compound E (lane 14, top panel). However, it was also 
noted that the level of Notch pulled down by Pen-2 antibody was more than that 
pulled down by PS1C antibody (compare lane 13 with 14), suggesting that the 
association between Pen-2 and Notch may be stronger than PS1 with Notch.  
To further determine the affinity of Pen-2 and PS1 for Notch, I performed the 
co-immunoprecipitation in Pen-2-knockout cells and PS1/2-double knockout 
cells. As a result, certain amount of NotchE was co-immunoprecipitated with 
Pen-2 in PS1/2-/- cells (lane 1, top panel). However, anti-PS1C antibody did not 
bring down any Notch in Pen-2 knockout cells (data not shown). Because PS1 is 
very unstable in Pen-2-/- cells, thus, this could be due to the low level of PS1 in 
Pen-2-/- cells. Therefore, I performed co-immunoprecipitation in Pen-2-/- cells 
transfected with PS1wt and it was found that only a negligible amount of 
NotchE was immunoprecipitated by anti-PS1C antibody in Pen-2-/- cells 
transfected with both PS1wt and NotchE, (lane 17, top panel). Again, this may 
be because of inefficient endoproteolytic processing of PS1 in the absence of 
Pen-2. Thus, I transfected Pen-2-/- cells with PS1N and PS1C, which have been 
shown to form active -secretase complex and process Notch in PS1/2-/- cells 
(figure 2.7). As a result, despite the fact that significant level of PS1C was 
detected in these cells (lane 5, third panel), no NotchE was co-
immunoprecipitated with PS1C (lane 5, top panel). These results revealed an 
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interesting finding that Pen-2 could interact with Notch in the absence of 
presenilin, however, presenilin could not interact with Notch in the absence of 
Pen-2, suggesting that presenilin interacts with Notch is mediated or enhanced 
by Pen-2. It was also noted that in the presence of overexpressed PS1, either 
PS1wt or PS1C, not only anti-PS1C antibody but also anti-Pen-2 antibody 
brought down more NotchE than in cells without overexpression of PS1 
(compare lanes 8 and 20 with lanes 11 and 14 for anti-PS1C antibody and 
compare lanes 7 and 19 with lanes 10 and 13 for anti-Pen-2 antibody). These 
results indicate that PS1 also enhances the interaction between Pen-2 and 
Notch. In addition, this set of experiments further confirmed that Notch is not 
processed in the absence of Pen-2 even in the presence of overexpressed PS1 
(lanes 6 and 18, second panel). It should be pointed out that the binds detected 
by NICD-specific antibody in anti-Pen-2 immunoprecipitated samples (lanes 1, 4, 
7, 10, 13, 16, and 19, second panel) are non-specific signals. It was also noted 
that in WT cells, anti-myc antibody could bring down PS1C (lanes 12 and 15, 
third panel), but not Pen-2 (lane 12 and 15, bottom panel). Also, in WT cells, anti-
PS1C antibody could bring down Pen-2 (lanes 11 and 14, bottom panel), but not 
in PS1/2-/- cells expressing PS1N and PS1C (lanes 8 and 20, bottom panel).  
 
Discussion 
 
Among the four components of -secretase complex, Pen-2 is the relatively less 
characterized member. Studies have suggested that Pen-2 plays a role in 
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presenilin endoproteolysis and stabilization and nicastrin maturation (Mao, Cui et 
al. 2012). Using knockout mouse model, a study hypothesized that Pen-2 is more 
than a structural component of the -secretase complex and may contribute to 
the catalytic mechanism of the enzyme (Bammens, Chávez-Gutiérrez et al. 
2011). In the study presented in this chapter, we used specific knockout cells in 
combination with siRNA technology to determine the role of Pen-2 in -secretase 
and the mechanism by which Pen-2 contribute to -secretase activity. The most 
interesting finding is that knockdown of NCT in Aph-1-/- cells had no significant 
effect on Notch processing. In chapter I, our data showed that knockout of either 
one of NCT and Aph-1 individually did not impair the enzymatic function of -
secretase to process Notch. This finding suggests a possibility that the presence 
of both of NCT and Aph-1 simultaneously is not required for Notch processing. In 
other words, either NCT or Aph-1 along with Pen-2 and PS1 will form a functional 
complex to process Notch. However, data presented in this chapter surprisingly 
demonstrated that the knockdown of NCT in Aph-1-/- cells had no significant 
effect on Notch processing. This finding strongly suggests that Pen-2 and PS1 
are the minimal required and sufficient to catalyze Notch processing. To further 
investigate the mechanism by which Pen-2 plays a directly role in Notch 
processing, our data revealed that Notch could not be co-immunoprecipitated 
with Pen-2 in PS1/2-/- double knockout cells, however, Notch was co-
immunoprecipitated with PS1 in Pen-2-/- cells. This result indicates that Notch 
interacts with Pen-2 in the absence of PS1, but PS1 can’t interact with Notch in 
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the absence of Pen-2. This finding strongly suggests a possibility that interaction 
between PS1 and Notch is mediated by Pen-2, i.e., Pen-2 functions as a receptor 
in recruiting substrate to -secretase complex. These novel findings revealed a 
important function of Pen-2 and will greatly contribute to our understanding of the 
molecular mechanism of -secretase activity.  
In addition, the data presented in this chapter lead to several interesting findings.       
    First, using the PS1/2-/- double knockout cells, our data clearly demonstrated 
that introduction of the PS1D257A and PS1D2385A point mutations in PS1 result in 
an inactive -secretase for processing Notch and this finding confirmed again that 
these two aspartyl residues are essential for -secretase activity as reported by 
previous study (Wolfe, Xia et al. 1999).  
    Second, our data demonstrated that all the PS1 C-terminal fragments 
produced during endoproteolysis and by caspase activity are functional in Notch 
processing when expressed along with PS1N. it has been reported that during 
maturation, PS1 undergoes endoproteolytic processing and the produced PS1N 
and PS1C fragments form heterodimer. Study also reported that, similar to APP, 
endoproteolysis of PS1 also follows a stepwise sequential cleavage and result in 
the formation of PS1Cs of different length of which PS1C299 is the major species 
(Fukumori, Fluhrer et al. 2010). Our data showed that co-expression of the 
PS1Cs with different length corresponding to the PS1Cs produced during 
endoproteolysis and by caspase activity along with PS1N resulted in Notch 
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processing. These results indicate that all these PS1Cs are functional in 
constituting active -secretase.  
    Third, Pen-2 is not required for PS1N and PS1C heterodimer formation. It has 
been concerned that the heterodimer of PS1N and PS1C might been disturbed in 
the absence of Pen-2 (reference is missing). However, the immunoprecipitation 
results demonstrated that the association of PS1N and PS1C were not affect by 
the deletion of Pen-2. Our finding is also supported by a previous study showing 
that Pen-2 did not enhance the level of heterodimer of PS1 (Shiraishi, Sai et al. 
2004). Combined together, it is clearly indicated that Pen-2 is directly involved in 
 secretase activity rather than indirectly by enhancing PS1N/PS1C heterodimer 
formation. 
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Figure 3.1 
 
Figure 3.1 Two aspartyl acids on PS1 were essential for the processing of Notch. 
Notch was overexpressed in PS1/2-/- cell with the transfection of NotchΔE and 
detected with -myc in the first panel. The processing of Notch was detected in 
the second panel with antibody C-Notch. Cells were also transfected with PS1 
WT and PS1 mutants: PS1D257A, PS1D385A and PS1D257,385A, the expression of 
PS1 and PS1 mutants were reflected with antibody PS1C 5643. GAPDH was 
applied as loading control as shown in the bottom panel.  
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Figure 3.2 
 
Figure 3.2 Pen-2 is directly required for Notch processing through -secretase.  
NotchΔE could not be processed by the double transfection of PS1C terminal 
fragments (all the truncated PS1 Cs) and PS1N fragments in Pen-2-/- cell. Pen-2 
knockout cells was transfected with different PS1 C terminals and PS1N 
terminals together with NotchΔE. And immunoblot probed with anti PS1C 
antibody 5643, -myc, c-Notch and GAPDH separately. 
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Figure 3.3 
 
Figure 3.3 Knockdown of NCT in Aph-1-/- cell does not affect the Notch 
processing. NotchΔE was overexpressed in Aph-1-/- cell and detected with -myc 
(first panel). PS1/2-/- and wt cell were used as control. Three NCT siRNA 
reagents (1,2 and 3) were applied and the knockdown results were detected in 
the third panel with antibody NCT. The processing of Notch was detected in the 
second panel with antibody C-Notch. GAPDH was applied as loading control as 
shown in the bottom panel.  
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Figure 3.4 
 
Figure 3.4 The association of PS1N and PS1C was not disturbed by the deletion 
of Pen-2. PS1N and varied PS1Cs (PS1C293,  PS1C296, PS1C299,  PS1C334,  
PS1C346) were transfected into Pen-2
-/- and PS1/2-/- cell. WT cell and Wt-7 cell 
were used as control.  Samples were immunoprecipitated with antibody PS1N 
and the association of PS1N and PS1C were indicated with the detection of PS1 
by the antibody PS1C 5643 (shown in the two panels).  
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Figure 3.5 
 
Figure 3.5 Pen-2 is required for Notch binding to PS1.Notch ΔE were transfected 
into Pen-2-/- , PS1/2-/- and WT cell and the expression were detected in the first 
row with -myc antibody. PS1WT plasmids and PS1C299, PS1N were transfected 
into Pen-2-/- and PS1/2-/- cell and detected with antibody 5643 in the third row. 
The processing of Notch was detected with antibody C-Notch in the second row. 
The level of Pen-2 was detected in bottom row with anti-Pen-2 antibody. All the 
samples were immunoprecipitated with varied antibodies: Pen-2, PS1C 5643 and 
-myc as indicated in the figure. As secretase inhibitor, CompE (5nM) was 
applied in WT cell.  
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CONCLUSION  
 
Since -secretase is the key enzyme in A production, it has attracted particular 
attention in Alzheimer’s disease research. However, despite of numerous studies 
that have focused on the structure and function of -secretase complex, there are 
still a lot of questions remaining to be answered regarding the biological function 
and specific role of each component in the -secretase complex. My study is 
mainly focused on the role of each secretase components in its activity and 
stability of the complex.  
In conclusion, the first finding of my research is that Aph-1 is dispensable for 
secretase activity of processing both APP and Notch.  
Second, our data revealed a very interesting finding that NCT is required for 
processing of APP, while it is not necessary for the processing of Notch. Even 
though the molecular mechanism of this finding needs to be further investigated, 
it opens a new avenue for searching for target of blocking production of 
Awithout affecting the signal transduction of NICD.  
Third and most importantly, our data revealed that Pen-2 and PS1 are the 
minimal required and essential components for constituting active secretase of 
processing Notch. As a mechanism, our data uncovered a novel function of Pen-
2 in binding and recruiting substrate Notch to secretase.  
In addition, our data also demonstrated that knockout of Aph-1 sensitizes cells 
to apoptotic stimuli.  
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